CA2874555A1 - Synthesis of pyrrolo [2, 3 - b] pyridines - Google Patents
Synthesis of pyrrolo [2, 3 - b] pyridines Download PDFInfo
- Publication number
- CA2874555A1 CA2874555A1 CA2874555A CA2874555A CA2874555A1 CA 2874555 A1 CA2874555 A1 CA 2874555A1 CA 2874555 A CA2874555 A CA 2874555A CA 2874555 A CA2874555 A CA 2874555A CA 2874555 A1 CA2874555 A1 CA 2874555A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- optionally substituted
- aryl
- 6alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
Abstract
Provided herein are intermediates and processes useful for facile synthesis of biologically active molecules. The intermediates are compounds of formula (I):
(see formula I)
(see formula I)
Description
SYNTHESIS OF PYRROLO [2, 3 - 13] PYRIDINES
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. 119(e) of United States Provisional Application No. 61/653,994, filed on May 31, 2012, which is incorporated by reference in its entirety.
FIELD OF THE INVENTION
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under 35 U.S.C. 119(e) of United States Provisional Application No. 61/653,994, filed on May 31, 2012, which is incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to heterocyclic compounds, methods for the preparation thereof, and compounds prepared employing same.
BACKGROUND OF THE INVENTION
BACKGROUND OF THE INVENTION
[0003] N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoro-phenyl]propane-1-sulfonamide or propane-l-sulfonic acid {3-[5-( 4-chloro-phenyl )-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl} -amide (Vemurafenib;
Zelborafrm) is effective for the treatment of various B-raf mediated diseases and conditions, including, but not limited to, metastatic melanoma, thyroid cancers and colorectal cancers (Nature, 2010, 467, 596-599; New England Journal of Medicine, 2010, 363, 80). The compound and its synthesis have been described in PCT Patent Publication Nos. WO 2007/002433 and WO
2007/002325. There remains interest in developing other versatile and facile processes for the efficient preparation of this and other biologically active molecules, especially, on an industrial scale.
SUMMARY OF THE INVENTION
Zelborafrm) is effective for the treatment of various B-raf mediated diseases and conditions, including, but not limited to, metastatic melanoma, thyroid cancers and colorectal cancers (Nature, 2010, 467, 596-599; New England Journal of Medicine, 2010, 363, 80). The compound and its synthesis have been described in PCT Patent Publication Nos. WO 2007/002433 and WO
2007/002325. There remains interest in developing other versatile and facile processes for the efficient preparation of this and other biologically active molecules, especially, on an industrial scale.
SUMMARY OF THE INVENTION
[0004] In one aspect, the present invention provides a compound of formula (I):
Q
0 .
I \ F
N N, p2 (I) The compound can be used as an intermediate for the synthesis of various biologically active molecules. In formula (I):
Q
0 .
I \ F
N N, p2 (I) The compound can be used as an intermediate for the synthesis of various biologically active molecules. In formula (I):
5 PCT/US2013/043400 Q is F or H;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
In one embodiment, P1 is H. In another embodiment, Q is F; P1 is H; and L1 is Br.
[0005] In another aspect, the present invention provides a method for preparing a compound of formula (I). The method comprises contacting a compound of formula (II):
Q
0 .
i =-=., \ F NH2 I
N N
H (II) with an agent having the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 e i =-,... \ F NH2 I
N N
iD2 (Ia);
and contacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I),wherein:
X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-;
X3 is a leaving group;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
In one embodiment, P1 is H. In another embodiment, Q is F; P1 is H; and L1 is Br.
[0005] In another aspect, the present invention provides a method for preparing a compound of formula (I). The method comprises contacting a compound of formula (II):
Q
0 .
i =-=., \ F NH2 I
N N
H (II) with an agent having the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 e i =-,... \ F NH2 I
N N
iD2 (Ia);
and contacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I),wherein:
X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-;
X3 is a leaving group;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-S020- or R2C(0)0; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl.
[0006] In yet another aspect, the present invention provides a method for preparing a compound of formula (III):
Q
0 =//0 Y
1 \ \ F H N1\
N N
H (III).
The method comprises (i) contacting a compound of formula (I) with an agent having the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula : Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 41k, Y
\ F NHP1 I
N N
\
p2 (IV), (ii) reacting a compound of formula (IV) with an agent of the formula : A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX);
Q
0 41k, Y 1 \ F HN-/\
N N
\
p2 (IX), and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S.
DETAILED DESCRIPTION OF THE INVENTION
Q
0 =//0 Y
1 \ \ F H N1\
N N
H (III).
The method comprises (i) contacting a compound of formula (I) with an agent having the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula : Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 41k, Y
\ F NHP1 I
N N
\
p2 (IV), (ii) reacting a compound of formula (IV) with an agent of the formula : A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX);
Q
0 41k, Y 1 \ F HN-/\
N N
\
p2 (IX), and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S.
DETAILED DESCRIPTION OF THE INVENTION
[0007] The present invention is related to novel synthetic intermediates and processes for the large-scale preparation of compounds that have the following core structure (aa):
/ 5 0 et I I
F
NH-S-I I I
N
(aa), namely, [2,6-difluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core or [2-fluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core.
The wavy lines indicate the points of attachment to the remainder of the structure. In some embodiments, the 5-position of the 7-azaindole ring in the core structure (aa) is occupied with the substituent Y and the sulfonyl group is linked to the substituent Z. The variables Q, Y
and Z are as defined in the Summary of the Invention and any of the embodiments as described herein. For example, the present invention provides synthetic methods and intermediates useful for the large scale preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoro-phenyl]propane-1-sulfonamides or propane-1-sulfonic acid {3-[5-( 4-chloro-phenyl )-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl} -amides. Advantageously, the present invention provides synthetic intermediates and versatile processes, which allow for high efficiency, low cost and large-scale facile synthesis of biologically active molecules including vemurafenib with high purity. The intermediates of the present invention can be readily adapted to the facile preparation of various compounds having core structure (aa).
Definitions
/ 5 0 et I I
F
NH-S-I I I
N
(aa), namely, [2,6-difluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core or [2-fluoro-3-(sulfonylamino)pheny1]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanone core.
The wavy lines indicate the points of attachment to the remainder of the structure. In some embodiments, the 5-position of the 7-azaindole ring in the core structure (aa) is occupied with the substituent Y and the sulfonyl group is linked to the substituent Z. The variables Q, Y
and Z are as defined in the Summary of the Invention and any of the embodiments as described herein. For example, the present invention provides synthetic methods and intermediates useful for the large scale preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluoro-phenyl]propane-1-sulfonamides or propane-1-sulfonic acid {3-[5-( 4-chloro-phenyl )-1H-pyrrolo[2,3-b]pyridine-3-carbony1]-2,4-difluorophenyl} -amides. Advantageously, the present invention provides synthetic intermediates and versatile processes, which allow for high efficiency, low cost and large-scale facile synthesis of biologically active molecules including vemurafenib with high purity. The intermediates of the present invention can be readily adapted to the facile preparation of various compounds having core structure (aa).
Definitions
[0008] It is noted here that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise.
[0009] "Halogen" or "halo" refers to all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), or iodo (I).
[0010] "Hydroxyl" or "hydroxy" refers to the group -OH.
[0011] "Thiol" refers to the group -SH.
[0012] The term "alkyl", by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain hydrocarbon, having the number of carbon atoms designated (i.e. C1-6 means one to six carbons). Representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms.
Further representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. For each of the definitions herein (e.g., alkyl, alkoxy, alkylamino, alkylthio, alkylene, haloalkyl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl), when a prefix is not included to indicate the number of carbon atoms in an alkyl portion, the alkyl moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms or 6 or fewer main chain carbon atoms. For example, C1_8 alkyl refers to a straight or branched hydrocarbon having 1, 2, 3, 4, 5 or 6 carbon atoms and includes, but are not limited to, Ci_2 alkyl, Ci_4 alkyl, C2_6 alkyl, C2_4 alkyl, Ci_6 alkyl, C2_8 alkyl, C1_7 alkyl, C2_7 alkyl and C3_6 alkyl. "Fluoro substituted alkyl" denotes an alkyl group substituted with one or more fluoro atoms, such as perfluoroalkyl, where preferably the lower alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms.
While it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as -OR (e.g.
alkoxy), -SR (e.g. thioalkyl), -NHR (e.g. alkylamino), -C(0)NHR, and the like, substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any 0, S, or N of the moiety (except where N is a heteroaryl ring atom) excludes substituents that would result in any 0, S, or N of the substituent (except where N is a heteroaryl ring atom) being bound to the alkyl carbon bound to any 0, S, or N of the moiety.
Further representative alkyl groups include straight and branched chain alkyl groups having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, and the like. For each of the definitions herein (e.g., alkyl, alkoxy, alkylamino, alkylthio, alkylene, haloalkyl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, heteroarylalkyl), when a prefix is not included to indicate the number of carbon atoms in an alkyl portion, the alkyl moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms or 6 or fewer main chain carbon atoms. For example, C1_8 alkyl refers to a straight or branched hydrocarbon having 1, 2, 3, 4, 5 or 6 carbon atoms and includes, but are not limited to, Ci_2 alkyl, Ci_4 alkyl, C2_6 alkyl, C2_4 alkyl, Ci_6 alkyl, C2_8 alkyl, C1_7 alkyl, C2_7 alkyl and C3_6 alkyl. "Fluoro substituted alkyl" denotes an alkyl group substituted with one or more fluoro atoms, such as perfluoroalkyl, where preferably the lower alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms.
While it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as -OR (e.g.
alkoxy), -SR (e.g. thioalkyl), -NHR (e.g. alkylamino), -C(0)NHR, and the like, substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any 0, S, or N of the moiety (except where N is a heteroaryl ring atom) excludes substituents that would result in any 0, S, or N of the substituent (except where N is a heteroaryl ring atom) being bound to the alkyl carbon bound to any 0, S, or N of the moiety.
[0013] The term "alkylene" by itself or as part of another substituent means a linear or branched saturated divalent hydrocarbon moiety derived from an alkane having the number of carbon atoms indicated in the prefix. For example, (i.e., C1_6 means one to six carbons; C1_ 6 alkylene is meant to include methylene, ethylene, propylene, 2-methylpropylene, pentylene, hexylene and the like). C1_4 alkylene includes methylene -CH2-, ethylene -CH2CH2-, propylene -CH2CH2CH2-, and isopropylene -CH(CH3)CH2- , -CH2CH(CH3)-, -CH2-(CH2)2CH2-, -CH2-CH(CH3)CH2-, -CH2-C(CH3)2-, -CH2-CH2CH(CH3)- . Typically, an alkyl (or alkylene) group will have from 1 to 24 carbon atoms, with those groups having 10 or fewer, 8 or fewer, or 6 or fewer carbon atoms being preferred in the present invention. When a prefix is not included to indicate the number of carbon atoms in an alkylene portion, the alkylene moiety or portion thereof will have 12 or fewer main chain carbon atoms or 8 or fewer main chain carbon atoms, 6 or fewer main chain carbon atoms or 4 or fewer main chain carbon atoms.
[0014] "Cycloalkylalkyl" refers to an -(alkylene)-cycloalkyl group where alkylene as defined herein has the indicated number of carbon atoms or if unspecified having six or fewer, preferably four or fewer main chain carbon atoms; and cycloalkyl is as defined herein has the indicated number of carbon atoms. C3_8cycloalkyl-Ci_2alkyl means C3_8cycloalkyl-C1_ 2alkylene, wherein the cycloalkyl has 3 to 8 ring carbon atoms and the alkylene has 1 or 2 carbon atoms. Exemplary cycloalkylalkyl include, e.g., cyclopropylmethylene, cyclobutylethylene, cyclobutylmethylene, and the like.
[0015] "Cycloalkyl" by itself or as part of another substituent, refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, 1-cyclohexenyl, adamantyl, and the like. Cycloalkyl refers to hydrocarbon rings having the indicated number of ring atoms (e.g., C3_8 cycloalkyl means three to eight ring carbon atoms).
[0016] "Haloalkyl," is meant to include alkyl substituted by one to seven halogen atoms.
Haloalkyl includes monohaloalkyl and polyhaloalkyl. For example, the term "C1-6 haloalkyl"
is meant to include trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
Haloalkyl includes monohaloalkyl and polyhaloalkyl. For example, the term "C1-6 haloalkyl"
is meant to include trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 4-chlorobutyl, 3-bromopropyl, and the like.
[0017] "Haloalkoxy" refers to a ¨0-haloalkyl group, where haloalkyl is as defined herein, e. g., trifluoromethoxy, 2,2,2-trifluoroethoxy, difluoromethoxy, and the like.
[0018] "Alkoxy" refers to a ¨0-alkyl group, where alkyl is as defined herein.
"Cycloalkoxy" refers to a ¨0-cycloalkyl group, where cycloalkyl is as defined herein.
"Fluoro substituted alkoxy" denotes alkoxy in which the alkyl is substituted with one or more fluoro atoms, where preferably the alkoxy is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions on alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that 0, S, or N
(except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy 0. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an 0, S, or N of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety.
"Cycloalkoxy" refers to a ¨0-cycloalkyl group, where cycloalkyl is as defined herein.
"Fluoro substituted alkoxy" denotes alkoxy in which the alkyl is substituted with one or more fluoro atoms, where preferably the alkoxy is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions on alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that 0, S, or N
(except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy 0. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an 0, S, or N of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety.
[0019] "Amino" or "amine" denotes the group -NH2.
[0020] "Alkylamino" refers to a ¨NH-alkyl group, where alkyl is as defined herein.
Exemplary alkylamino groups include CH3NH-, ethylamino, and the like.
Exemplary alkylamino groups include CH3NH-, ethylamino, and the like.
[0021] "Dialkylamino" refers to a ¨N(alkyl)(alkyl) group, where each alkyl is independently as defined herein. Exemplary dialkylamino groups include dimethylamino, diethylamino, ethylmethylamino, and the like.
[0022] "Cycloalkylamino" denotes the group -NRddRee, where Rdd and Ree combine with the nitrogen to form a 5-7 membered heterocycloalkyl ring, where the heterocycloalkyl may contain an additional heteroatom within the ring, such as 0, N, or S, and may also be further substituted with alkyl, haloalkyl, haloalkoxy, alkoxy, aryl, heteroaryl, arylalkyl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl or R' as defined herein.
Alternatively, "cycloalkylamino" refers to a ¨NH-cycloalkyl group, where cycloalkyl is as defined herein.
Alternatively, "cycloalkylamino" refers to a ¨NH-cycloalkyl group, where cycloalkyl is as defined herein.
[0023] "Arylamino" refers to a ¨NH-aryl group, where aryl is as defined herein.
Exemplary arylamino groups include PhNH-, naphthylamino, and the like.
Exemplary arylamino groups include PhNH-, naphthylamino, and the like.
[0024] "Heteroarylamino" refers to a ¨NH-heteroaryl group, where heteroaryl is as defined herein. Exemplary heteroarylamino groups include pyridinyl-NH-, pyrimidinyl-amino, and the like.
[0025] "Aryl" by itself or as part of another substituent refers to a monocyclic, bicyclic or polycyclic polyunsaturated aromatic hydrocarbon moiety containing 6 to 14 ring carbon atoms. Non-limiting examples of unsubstituted aryl groups include phenyl, 1-naphthyl, 2-naphthyl and 4-biphenyl. Exemplary aryl group, such as phenyl or naphthyl, which may be optionally fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members.
[0026] "Arylalkyl" refers to -(alkylene)-aryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and aryl is as defined herein.
For example, aryl-Ci_2alkyl means aryl-alkylene-, where the alkylene has 1 or 2 carbon atoms. Examples of arylalkyl include benzyl, phenethyl, and the like.
For example, aryl-Ci_2alkyl means aryl-alkylene-, where the alkylene has 1 or 2 carbon atoms. Examples of arylalkyl include benzyl, phenethyl, and the like.
[0027] "Heteroaryl" by itself or as part of another substituent refers to a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group consisting of 0, S, and N.
Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, indolyl, triazinyl, quinoxalinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzothienyl, quinolyl, isoquinolyl, indazolyl, pteridinyl and thiadiazolyl. "Nitrogen containing heteroaryl"
refers to heteroaryl wherein any heteroatoms are N.
Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, pyrazolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazolyl, furanyl, benzofuryl, indolyl, triazinyl, quinoxalinyl, cinnolinyl, phthalaziniyl, benzotriazinyl, benzimidazolyl, benzopyrazolyl, benzotriazolyl, benzisoxazolyl, isobenzofuryl, isoindolyl, indolizinyl, benzotriazinyl, thienopyridinyl, thienopyrimidinyl, pyrazolopyrimidinyl, imidazopyridines, benzothiaxolyl, benzothienyl, quinolyl, isoquinolyl, indazolyl, pteridinyl and thiadiazolyl. "Nitrogen containing heteroaryl"
refers to heteroaryl wherein any heteroatoms are N.
[0028] "Heteroarylalkyl" refers to -(alkylene)-heteroaryl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heteroaryl is as defined herein. . For example, heteroaryl-Ci_2alkyl means heteroaryl-alkylene-, where the alkylene has 1 or 2 carbon atoms. Examples of heteroarylalkyl include 2-pyridylmethyl, 2-thiazolylethyl, and the like.
[0029] "Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic cycloalkyl group that contains from one to five heteroatoms selected from N, 0, and S, wherein the nitrogen and sulfur atoms are optionally oxidized, and the nitrogen atom(s) are optionally quaternized, the remaining ring atoms being C, where one or two C atoms may optionally be replaced by a carbonyl. The heterocycloalkyl may be a monocyclic, a bicyclic or a polycylic ring system of 3 to 12, preferably 4 to 10 ring atoms, more preferably 5 to 8 ring atoms, even more preferably 4-6 ring atoms in which one to five ring atoms are heteroatoms selected from ¨N=, -N-, -0-, -S-, -5(0)-, or ¨S(0)2- and further wherein one or two ring atoms are optionally replaced by a -C(0)- group. The heterocycloalkyl can also be a heterocyclic alkyl ring fused with a cycloalkyl, an aryl or a heteroaryl ring. Non limiting examples of heterocycloalkyl groups include pyrrolidinyl, piperidinyl, imidazolidinyl, pyrazolidinyl, butyrolactam moiety, valerolactam moiety, imidazolidinone moiety, hydantoin, dioxolane moiety, phthalimide moiety, piperidine, 1,4-dioxane moiety, morpholinyl, thiomorpholinyl, thiomorpholinyl-S-oxide, thiomorpholinyl-S,S-oxide, piperazinyl, pyranyl, pyridine moiety, 3-pyrrolinyl, thiopyranyl, pyrone moiety, tetrahydrofuranyl, tetrahydrothiophenyl, quinuclidinyl, and the like. A heterocycloalkyl group can be attached to the remainder of the molecule through a ring carbon or a heteroatom.
[0030] "Heterocycloalkylalkyl" refers to -(alkylene)-heterocycloalkyl, where the alkylene group is as defined herein and has the indicated number of carbon atoms, or if unspecified having six or fewer main chain carbon atoms or four or fewer main chain carbon atoms; and heterocycloalkyl is as defined herein. Examples of heterocycloalkylalkyl include 2-pyridylmethyl, 2-thiazolylethyl, and the like.
[0031] The substituents for alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, cycloalkylalkyl, alkylene, vinyl include, but are not limited to, R', halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR', -SR', -0C(0)R', -0C(S)R', -C(0)R', -C(S)R', -C(0)OR', -C(S)OR', -S(0)R', -S(0)2R', -C(0)NHR', -C(S)NHR', -C(0)NR'R", -C(S)NR'R", -S(0)2NHR', -S(0)2NR'R", -C(NH)NHR', -C(NH)NR'R'', -NHC(0)R', -NHC(S)R', -NR"C(0)R', -NR'C(S)R", -NHS(0)2R', -NR'S(0)2R", -NHC(0)NHR', -NHC(S)NHR', -NR'C(0)NH2, -NR'C(S)NH2, -NR'C(0)NHR", -NR'C(S)NHR", -NHC(0)NR'R", -NHC(S)NR'R'', -NR'C(0)NR"R''', -NR'''C(S)NR'R", -NHS(0)2NHR', -NR'S(0)2NH2, -NR'S(0)2NHR", -NHS(0)2NR'R", -NR'S(0)2NR''R''', -NHR', and -NR'R" in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such group.
R', R" and R" each independently refer to hydrogen, C1-8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-CI-4 alkyl groups.
When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. R', R" and R" can be further substituted with Rai, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Ral, -Se, -0C(0)Ral, -0C(S)Ral, -C(0)Ral, -C(S)Ral, -C(0)0Ral, -C(S)OR, -S(0)Ral, -S(0)2Ral, -C(0)NHRal, -C(S)NHRal, -C(0)NRale, -C(S)NRale, -S(0)2NHRal, -S(0)2NRale, -C(NH)NHRal, -C(NH)NR Ra2, -NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral, -NR C(S)Ra2, -NHS(0)2Ral, -NRalS(0)2e, -NHC(0)NHRal, -NHC(S)NHRal, -NRalC(0)NH2, -NRalC(S)NH2, -NRalC(0)NHRa2, -NRalC(S)NHRa2, -NHC(0)NRale, -NHC(S)NRale, -NRalC(0)Nele, -NRa3C(S)NRale, -NHS(0)2NHRal, -NRalS(0)2NH2, -NRalS(0)2NHe, -NHS(0)2NRale, -NRalS(0)2Nele, -NHRal, and -NRale in a number ranging from zero to (2n'+1), where n' is the total number of carbon atoms in such group. Rai, Ra2 and e each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups. Rai, Ra2 and e can be further substituted with Rbi, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -ORbi, -SRbi, -0C(0)Rbi, -0C(S)Rbi, -C(0)Rbi, -C(S)Rbi, -C(0)0Rbi, -C(S)ORbi, -S(0)Rbi, -S(0)2Rbi, -C(0)NHRb1, -C(S)NHRbi, -C(0)NRbiRb2, -C(S)NRbiRb2, -S(0)2NHRbi, -S(0)2NRbiRb2, -C(NH)NHRbi, -C(NH)NRbiRb2, -NHC(0)Rbi, -NHC(S)Rbi, -NRb2C(0)Rbi , -NRb 1 C(S)Rb2, -NHS(0)2Rbi , -NRbl S(0)2Rb2, -NHC(0)NHRb1 , -NHC(S)NHRbl, -NRb1C(0)NH2, -NR' c(s)NH2, -NR'1C(0)NHRb2, -NRb1C(S)NHRb2, -NHC(0)NRblRb2, -NHC(S)NRblRb2, -NRb1C(0)NRb2Rb3, -NRb3C(S)NRblRb2, -NHS (0)2NHRbl, -NRb1S(0)2NH2, -NR11S(0)2NHRb2, -NHS (0)2NRblRb2, -NRb1S(0)2NRb2Rb3, -NHRbl, and -NRb1Rb2 in a number ranging from zero to (2p'+1), where p' is the total number of carbon atoms in such group. Rbi, Rb2 and Rb3 each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups.
R', R" and R" each independently refer to hydrogen, C1-8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-CI-4 alkyl groups.
When R' and R" are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 3-, 4-, 5-, 6-, or 7-membered ring. For example, -NR'R" is meant to include 1-pyrrolidinyl and 4-morpholinyl. R', R" and R" can be further substituted with Rai, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Ral, -Se, -0C(0)Ral, -0C(S)Ral, -C(0)Ral, -C(S)Ral, -C(0)0Ral, -C(S)OR, -S(0)Ral, -S(0)2Ral, -C(0)NHRal, -C(S)NHRal, -C(0)NRale, -C(S)NRale, -S(0)2NHRal, -S(0)2NRale, -C(NH)NHRal, -C(NH)NR Ra2, -NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral, -NR C(S)Ra2, -NHS(0)2Ral, -NRalS(0)2e, -NHC(0)NHRal, -NHC(S)NHRal, -NRalC(0)NH2, -NRalC(S)NH2, -NRalC(0)NHRa2, -NRalC(S)NHRa2, -NHC(0)NRale, -NHC(S)NRale, -NRalC(0)Nele, -NRa3C(S)NRale, -NHS(0)2NHRal, -NRalS(0)2NH2, -NRalS(0)2NHe, -NHS(0)2NRale, -NRalS(0)2Nele, -NHRal, and -NRale in a number ranging from zero to (2n'+1), where n' is the total number of carbon atoms in such group. Rai, Ra2 and e each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups. Rai, Ra2 and e can be further substituted with Rbi, halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -ORbi, -SRbi, -0C(0)Rbi, -0C(S)Rbi, -C(0)Rbi, -C(S)Rbi, -C(0)0Rbi, -C(S)ORbi, -S(0)Rbi, -S(0)2Rbi, -C(0)NHRb1, -C(S)NHRbi, -C(0)NRbiRb2, -C(S)NRbiRb2, -S(0)2NHRbi, -S(0)2NRbiRb2, -C(NH)NHRbi, -C(NH)NRbiRb2, -NHC(0)Rbi, -NHC(S)Rbi, -NRb2C(0)Rbi , -NRb 1 C(S)Rb2, -NHS(0)2Rbi , -NRbl S(0)2Rb2, -NHC(0)NHRb1 , -NHC(S)NHRbl, -NRb1C(0)NH2, -NR' c(s)NH2, -NR'1C(0)NHRb2, -NRb1C(S)NHRb2, -NHC(0)NRblRb2, -NHC(S)NRblRb2, -NRb1C(0)NRb2Rb3, -NRb3C(S)NRblRb2, -NHS (0)2NHRbl, -NRb1S(0)2NH2, -NR11S(0)2NHRb2, -NHS (0)2NRblRb2, -NRb1S(0)2NRb2Rb3, -NHRbl, and -NRb1Rb2 in a number ranging from zero to (2p'+1), where p' is the total number of carbon atoms in such group. Rbi, Rb2 and Rb3 each independently refer to hydrogen, C1_8 alkyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, aryl substituted with 1-3 halogens, C1-8 alkoxy, haloalkyl, haloalkoxy or C1-8 thioalkoxy groups, or unsubstituted aryl-C1-4 alkyl groups.
[0032] Substituents for the aryl and heteroaryl groups are varied and are generally selected from: R', halogen, -OH, -NH2, -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR', -SR', -0C(0)R', -0C(S)R', -C(0)R', -C(S)R', -C(0)OR', -C(S)OR', -S(0)R', -S(0)2R', -C(0)NHR', -C(S)NHR', -C(0)NR'R'', -C(S)NR'R", -S(0)2NHR', -S(0)2NR'R", -C(NH)NHR', -C(NH)NR'R", -NHC(0)R', -NHC(S)R', -NR"C(0)R', -NR'C(S)R", -NHS(0)2R', -NR'S(0)2R", -NHC(0)NHR', -NHC(S)NHR', -NR'C(0)NH2, -NR'C(S)NH2, -NR'C(0)NHR'', -NR'C(S)NHR'', -NHC(0)NR'R'', -NHC(S)NR'R'', -NR'C(0)NR''R-, -NR¨C(S)NR'R", -NHS(0)2NHR', -NR'S(0)2NH25 -NR'S(0)2NHR", -NHS(0)2NR'R", -NR'S(0)2NR"R''', -NHR', -NR'R", -N35 perfluoro(Ci-C4)alkoxy, and perfluoro(Ci-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where R', R" and R" are independently selected from hydrogen, haloalkyl, haloalkoxy, C1_8 alkyl, C3_6 cycloalkyl, cycloalkylalkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl-CI-4 alkyl, and aryloxy-C 1-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms. R', R" and R" can be further substituted with Rai, halogen, -OH, -NH25 -NO2, -CN, -C(0)0H, -C(S)OH, -C(0)NH25 -C(S)NH25 -S(0)2NH25 -NHC(0)NH25 -NHC(S)NH25 -NHS(0)2NH25 -C(NH)NH25 -0Ral, -SRal, -0C(0)Ral, -0C(S)Ral -C(0)Ral, -C(S)Ral, -C(0)0Ral -C(S)0Ral -S(0)Ral, -S(0)2Ral -C(0)NHRal, -C(S)NHRal -C(0)NRK
al a25 C(S)NRKal a2 5 S(0)2NHRal, -S(0)2NRal Ka2 5 C(NH)NHRal, -C(NH)NRal Ka2 NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral -NRal C(S)Ra2, -NHS(0)2Ral, -NRal S(0)2Ra2, -NHC(0)NHRal -NHC(S)NHRal, -NRalC(0)NH25 -NRal C(S)NH25 -NRal C(0)NHRa2, -NRal C(S)NHRa2, -NHC(0)NRal,. a25 NHC(S)NRaiRa25 -NRalC(0)NRa2 a3 5 K NRa3C(S)NRaK
l a25 NHS(0)2NHRal, -NRal S(0)2NH25 -NRalS(0)2NHRa2, -NHS(0)2NRalRa25 ----NK al S(0)2NRa2Ra3 5 NHRal 5 NRalRa2 5 5 perfluoro(Ci-C4)alkoxy, and perfluoro(Ci-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where Rai, Ra2 and e are each independently selected from hydrogen, haloalkyl, haloalkoxy, C1_8 alkyl, C3_6 cycloalkyl, cycloalkylalkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl-Ci-4 alkyl, or aryloxy-Ci-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.
al a25 C(S)NRKal a2 5 S(0)2NHRal, -S(0)2NRal Ka2 5 C(NH)NHRal, -C(NH)NRal Ka2 NHC(0)Ral, -NHC(S)Ral, -NRa2C(0)Ral -NRal C(S)Ra2, -NHS(0)2Ral, -NRal S(0)2Ra2, -NHC(0)NHRal -NHC(S)NHRal, -NRalC(0)NH25 -NRal C(S)NH25 -NRal C(0)NHRa2, -NRal C(S)NHRa2, -NHC(0)NRal,. a25 NHC(S)NRaiRa25 -NRalC(0)NRa2 a3 5 K NRa3C(S)NRaK
l a25 NHS(0)2NHRal, -NRal S(0)2NH25 -NRalS(0)2NHRa2, -NHS(0)2NRalRa25 ----NK al S(0)2NRa2Ra3 5 NHRal 5 NRalRa2 5 5 perfluoro(Ci-C4)alkoxy, and perfluoro(Ci-C4)alkyl, in a number ranging from zero to the total number of open valences on the aromatic ring system; and where Rai, Ra2 and e are each independently selected from hydrogen, haloalkyl, haloalkoxy, C1_8 alkyl, C3_6 cycloalkyl, cycloalkylalkyl, C2_8 alkenyl, C2_8 alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, aryl-Ci-4 alkyl, or aryloxy-Ci-4 alkyl. Other suitable substituents include each of the above aryl substituents attached to a ring atom by an alkylene tether of from 1-4 carbon atoms.
[0033] When two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula ¨T-C(0)-(CH2)q-U-5 wherein T and U are independently -NH-5 -0-, -CH2- or a single bond, and q is an integer of from 0 to 2. Alternatively, when two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula -A-(CH2),-B-5 wherein A and B are independently -CH2-5 -0-, -NH-5 -S-5 -S(0)-5 -S(0)2-5 -S(0)2NR'- or a single bond, and r is an integer of from 1 to 3. One of the single bonds of the new ring so formed may optionally be replaced with a double bond. Alternatively, when two substituents are present on adjacent atoms of a substituted aryl or a substituted heteroaryl ring, such substituents may optionally be replaced with a substituent of the formula -(CH2)s-X-(CH2)t-, where s and t are independently integers of from 0 to 3, and Xis -0-, -NR'-, -S-, -S(0)-, -S(0)2-, or -S(0)2NR'-. The substituent R' in -NR'- and -S(0)2NR'- is selected from hydrogen or unsubstituted C1-6 alkyl.
[0034] "Protecting group" refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G. WutS, PROTECTIVE GROUPS IN ORGANIC
CHEMISTRY, (Wiley, 4th ed. 2006), Beaucage and Iyer, Tetrahedron 48:2223-2311 (1992), and Harrison and Harrison et at., COMPENDIUM OF SYNTHETIC ORGANIC METHODS, Vols. 1-8 (John Wiley and Sons. 1971-1996). Representative amino protecting groups include formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), tri-isopropylsilyl (TIPS), phenylsulphonyl and the like (see also, Boyle, A. L.
(Editor), carbamates, amides, N-sulfonyl derivatives, groups of formula -C(0)0R, wherein R
is, for example, methyl, ethyl, t-butyl, benzyl, phenylethyl, CH2=CHCH2-, and the like, groups of the formula -C(0)R', wherein R' is, for example, methyl, phenyl, trifluoromethyl, and the like, groups of the formula -502R", wherein R" is, for example, tolyl, phenyl, trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl, 2,3,6-trimethy1-4-methoxyphenyl, and the like, and silanyl containing groups, such as 2-trimethylsilylethoxymethyl, t-butyldimethylsilyl, triisopropylsilyl, and the like, CURRENT PROTOCOLS IN
NUCLEIC ACID
CHEMISTRY, John Wiley and Sons, New York, Volume 1, 2000).
CHEMISTRY, (Wiley, 4th ed. 2006), Beaucage and Iyer, Tetrahedron 48:2223-2311 (1992), and Harrison and Harrison et at., COMPENDIUM OF SYNTHETIC ORGANIC METHODS, Vols. 1-8 (John Wiley and Sons. 1971-1996). Representative amino protecting groups include formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), tri-isopropylsilyl (TIPS), phenylsulphonyl and the like (see also, Boyle, A. L.
(Editor), carbamates, amides, N-sulfonyl derivatives, groups of formula -C(0)0R, wherein R
is, for example, methyl, ethyl, t-butyl, benzyl, phenylethyl, CH2=CHCH2-, and the like, groups of the formula -C(0)R', wherein R' is, for example, methyl, phenyl, trifluoromethyl, and the like, groups of the formula -502R", wherein R" is, for example, tolyl, phenyl, trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl, 2,3,6-trimethy1-4-methoxyphenyl, and the like, and silanyl containing groups, such as 2-trimethylsilylethoxymethyl, t-butyldimethylsilyl, triisopropylsilyl, and the like, CURRENT PROTOCOLS IN
NUCLEIC ACID
CHEMISTRY, John Wiley and Sons, New York, Volume 1, 2000).
[0035] The term "Labile protecting group" refers to those protecting groups that are removable under mild conditions that do not significantly impact other protecting groups or the remainder of the molecule.
[0036] The term "Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy, trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, N,0-dimethylhydroxylamino, and the like.
Compounds
Compounds
[0037] In one aspect, the present invention provides a compound of formula (I):
Q
0 =
I \ F
N N
iD2 (I) wherein the substituents P1, P2, L1 and Q are as defined in the Summary of the Invention. In one embodiment, P1 is H. The compounds of formula (I) are useful intermediates for the synthesis of various biologically active molecules, for example, compounds of formula (III):
Q
0 46, /,0 Y 1 \ F HN1\
N N
H (III) wherein Y is optionally substituted aryl or optionally substituted heteroaryl;
Z is optionally substituted Ci_6alkyl, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted cycloalkylamino, optionally substituted arylamino, optionally substituted heteroarylamino or NH2. Q is H or F. In one embodiment, Q is F.
Q
0 =
I \ F
N N
iD2 (I) wherein the substituents P1, P2, L1 and Q are as defined in the Summary of the Invention. In one embodiment, P1 is H. The compounds of formula (I) are useful intermediates for the synthesis of various biologically active molecules, for example, compounds of formula (III):
Q
0 46, /,0 Y 1 \ F HN1\
N N
H (III) wherein Y is optionally substituted aryl or optionally substituted heteroaryl;
Z is optionally substituted Ci_6alkyl, optionally substituted alkylamino, optionally substituted dialkylamino, optionally substituted cycloalkylamino, optionally substituted arylamino, optionally substituted heteroarylamino or NH2. Q is H or F. In one embodiment, Q is F.
[0038] In certain embodiments of compounds of formula (I), P1 can be selectively removed in the presence of the P2 group. Selective cleavage of P1 can be accomplished by adjusting the reaction conditions, such as temperature, pH, reaction time and so forth.
In some embodiments, P1 is a labile amino protecting group. Exemplary labile protecting group includes 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In a preferred embodiment, P1 is H.
In some embodiments, P1 is a labile amino protecting group. Exemplary labile protecting group includes 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In a preferred embodiment, P1 is H.
[0039] In certain embodiments of compounds of formula (I), P2 is an amino protecting group, which is capable of forming a carbamate or an amide linkage with the amino group to which it is attached. In some embodiments, P2 is an amino protecting group selected from R3-C(0)- or R40-C(0)-, wherein R3 and R4 are each independently selected from Ci_6alkyl, aryl, heteroaryl, aryl-Ci_2alkyl, heteroaryl-Ci_2alkyl, C3_10cycloalkyl, C3_10cycloalkyl-C1_ 2alkyl, ethynyl or vinyl, each of which is optionally substituted. In certain instances, R3 and R4 are each independently selected from Ci_6alkyl, aryl, heteroaryl, aryl-Ci_2alkyl, heteroaryl-Ci_2alkyl, C3_10cycloalkyl, C3_10cycloalkyl-Ci_2alkyl, ethynyl or vinyl, each of which is optionally substituted with 1-3 Ra groups independently selected from halogen, Ci_6alkyl, Ci-6haloalkyl, Ci_6haloalkoxy, fluoro substituted Ci_6alkyl, fluoro substituted Ci_6alkoxy, aryl, heteroaryl, Ci_6alkoxy, -CN, -NO2, -OH, Ci_6alkyl-OC(0)-, Ci_6alkyl-C(0)0- or -SiMe3, wherein the aliphatic or aromatic portion of Ra is further optionally substituted with from 1-3 Rb groups independently selected from halogen, Ci_6alkyl, Ci_6alkoxy, -CN, -NO2 or -OH. In other instances, R3 and R4 are each independently methyl, ethyl, phenyl, 2,2,2-trichloroethyl, (CH3)2CHCC-, 2-trimethylsilylethyl, 1-methyl-l-phenylethyl, cyclobutyl, cyclopropyl, allyl, vinyl, 1-adamantyl, benzyl or diphenylmethyl, each of which is optionally substituted with from 1-3 Ra groups. In some embodiments, Ra is F, Cl, Br, I, -CH3, Phenyl, t-butyl, Me0-, -NO2, -CN, -CF3, CF30-, -OH or -CH=CH2. In one embodiment, P2 is 2,6-dichlorophenylcarbonyl. In another embodiment, P2 is 2,5-dichlorophenylcarbonyl, 2,3-dichlorophenylcarbonyl or 2,4-dichlorophenylcarbonyl. In certain embodiments, P2 is phenylcarbonyl optionally substituted with from 1-2 groups independently selected from F, Cl, Br, CN or NO2. In some embodiments of compounds of formula (I), P2 is H.
All the other variables L1, P1 and Q are as defined in any of the embodiments described herein.
All the other variables L1, P1 and Q are as defined in any of the embodiments described herein.
[0040] In some embodiments of compounds of formula (I), L1 is Br, Cl, I, tosy1-0-, mesyl-0-, trifluoromethanesulfony1-0-, R1-S020- or R2C(0)0, wherein R1 and R2 are each independently selected from aryl, aryl-Ci_4alkyl or Ci_6alkyl, each of which is optionally substituted with from 1-3 Rc substituents selected from halogen, -CH=CH2, -CN, -OH, -NH2, -NO2, -C(0)0H, -C(0)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -ORd, -SR', -0C(0)Rd, -C(0)Rd, -C(0)OR', -C(S)OR', -S(0)Rd, -S(0)2R', -C(0)NHRd, -C(0)NRdRd, -S(0)2NHRd, -S(0)2NRdRd, -C(NH)NHRd, -C(NH)NRdRd, -NHC(0)Rd, -NRdC(0)Rd, -NHS(0)2R', -NRdS(0)2Rd, -NHC(0)NHRd, -NHRd or -NRdRd, wherein each Rd is independently selected from Ci_6alkyl or aryl. In some instances, Rd is -CH3, ethyl or phenyl. In some embodiments, L1 is Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. In one embodiment, L1 is Br or Cl.
All the other variables, P1, P2 and Q are as defined in any of the embodiments described herein.
All the other variables, P1, P2 and Q are as defined in any of the embodiments described herein.
[0041] In one embodiment of compounds of formula (I), P1 is H; and Q is F. In another embodiment, P1 and Q are H. In yet another embodiment, P1 is H; L1 is Br or Cl; and Q is F.
In a preferred embodiment of compounds of formula (I), L1 is Br or Cl; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
Methods
In a preferred embodiment of compounds of formula (I), L1 is Br or Cl; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
Methods
[0042] In another aspect, the present invention provide a method for preparing a compound of formulas (I) and (Ia). The method comprises contacting/reacting a compound of formula (II):
Q
0 =
i =-=, \ F NH2 I
N N
H (II) with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 46, , ,....... , F NH2 I
N N
iD2 (Ia); and contacting/reacting a compound of formula (Ia) with an agent of the formula:
P1-X3 under conditions sufficient to form the compound of formula (I). Alternatively, compound of formula (I) can also be prepared by first reacting a compound of formula (II) with an agent of the formula: P1-X3 to form an intermediate product, followed by reacting the intermediate product with an agent of the formula: P2-X1. X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. X3 is a leaving group. In one embodiment, X3 is Cl, Br, I, tosy1-0-, mesy1-0, CF3S(0)20-, CF3C(0)0- or CH3C(0)0-. P1 is a labile protecting group. In one embodiment, P1 is 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In one embodiment, P2 is H. In another embodiment, P2 is an amino protecting group as found in T.W. Greene and P.G.
Wuts, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, (Wiley, 4th ed. 2006) or as defined in any of the embodiments described herein. Q is H or F. L1 is Br, Cl, I, R1-S020- or R2C(0)0, wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl. In some embodiments, R1 and R2 are each independently selected from aryl, aryl-Ci_4alkyl or C1-6alkyl, each of which is optionally substituted with from 1-3 Rc substituents, wherein each Rd is independently selected from Ci_6alkyl or aryl. In some instances, Rd is ¨CH3, ethyl or phenyl. In some embodiments, L1 is Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0-or CH3C(0)0-. In a preferred embodiment, L1 is Br or Cl.
Q
0 =
i =-=, \ F NH2 I
N N
H (II) with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
Q
0 46, , ,....... , F NH2 I
N N
iD2 (Ia); and contacting/reacting a compound of formula (Ia) with an agent of the formula:
P1-X3 under conditions sufficient to form the compound of formula (I). Alternatively, compound of formula (I) can also be prepared by first reacting a compound of formula (II) with an agent of the formula: P1-X3 to form an intermediate product, followed by reacting the intermediate product with an agent of the formula: P2-X1. X1 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. X3 is a leaving group. In one embodiment, X3 is Cl, Br, I, tosy1-0-, mesy1-0, CF3S(0)20-, CF3C(0)0- or CH3C(0)0-. P1 is a labile protecting group. In one embodiment, P1 is 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl. In one embodiment, P2 is H. In another embodiment, P2 is an amino protecting group as found in T.W. Greene and P.G.
Wuts, PROTECTIVE GROUPS IN ORGANIC CHEMISTRY, (Wiley, 4th ed. 2006) or as defined in any of the embodiments described herein. Q is H or F. L1 is Br, Cl, I, R1-S020- or R2C(0)0, wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted Ci_6alkyl. In some embodiments, R1 and R2 are each independently selected from aryl, aryl-Ci_4alkyl or C1-6alkyl, each of which is optionally substituted with from 1-3 Rc substituents, wherein each Rd is independently selected from Ci_6alkyl or aryl. In some instances, Rd is ¨CH3, ethyl or phenyl. In some embodiments, L1 is Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0-or CH3C(0)0-. In a preferred embodiment, L1 is Br or Cl.
[0043] In some embodiments, the reactions for preparing compounds of formulas (I) or (Ia) can be carried out in the presence of a base dissolved in an organic solvent.
Some preferred bases include dimethylaminopyridine (DMAP), triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) and combinations thereof DMAP is generally present in a catalytic amount of about 0.05, 0.07, 0.08, 0.1, 0.2, 0.3, 0.4 or 0.5 equivalents. TEA or DIPEA can range from about 1-5 equivalents, for example, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents. The organic solvents used include, but are not limiting to, tetrahydrofuran (THF), 2-methyl-THF, acetonitrile, dichloromethane and benzene. A preferred solvent is 2-methyl-THF. The solvents can be present in various volumes, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 12 volumes.
Some preferred bases include dimethylaminopyridine (DMAP), triethylamine (TEA), N,N-diisopropylethylamine (DIPEA) and combinations thereof DMAP is generally present in a catalytic amount of about 0.05, 0.07, 0.08, 0.1, 0.2, 0.3, 0.4 or 0.5 equivalents. TEA or DIPEA can range from about 1-5 equivalents, for example, 1.0, 2.0, 3.0, 4.0 or 5.0 equivalents. The organic solvents used include, but are not limiting to, tetrahydrofuran (THF), 2-methyl-THF, acetonitrile, dichloromethane and benzene. A preferred solvent is 2-methyl-THF. The solvents can be present in various volumes, e.g., 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 12 volumes.
[0044] Compounds of formula (II) can be prepared by contacting a compound of formula (V):
Q
0 =
I \ F NO2 N N
H (V) with a reducing agent under conditions sufficient to form the compounds of formula (II). The variables, L1 and Q are as defined in any of the embodiments described herein.
In one embodiment, L1 is Br and Q is F. The reducing agent may be, but is not limited to, tin chloride dihydrate (SnC12=2H20). Typically, 1-5 equivalents (e.g., 1, 2, 3, 4 or 5 eqs) of the reducing agent are used. The reaction can be carried out at a temperature of about 40-90 C, preferably about 50-70 C, more preferably about 60 C. The solvents for the reaction can be 2-methyl-THF or a mixture of 1:1 ethyl acetate/THF. The volumes of the solvents can be from about 5 to 100 or about 7 to 80. In one embodiment, a compound of formula (V) is treated with 3 or 4 equivalents of SnC12 in 80 volumes of 1;1 ethyl acetate/THF or 7 volumes of 2-methyl THF at 60 C.
Q
0 =
I \ F NO2 N N
H (V) with a reducing agent under conditions sufficient to form the compounds of formula (II). The variables, L1 and Q are as defined in any of the embodiments described herein.
In one embodiment, L1 is Br and Q is F. The reducing agent may be, but is not limited to, tin chloride dihydrate (SnC12=2H20). Typically, 1-5 equivalents (e.g., 1, 2, 3, 4 or 5 eqs) of the reducing agent are used. The reaction can be carried out at a temperature of about 40-90 C, preferably about 50-70 C, more preferably about 60 C. The solvents for the reaction can be 2-methyl-THF or a mixture of 1:1 ethyl acetate/THF. The volumes of the solvents can be from about 5 to 100 or about 7 to 80. In one embodiment, a compound of formula (V) is treated with 3 or 4 equivalents of SnC12 in 80 volumes of 1;1 ethyl acetate/THF or 7 volumes of 2-methyl THF at 60 C.
[0045] Compounds of formula (V) can be prepared by reacting a compound of formula (VI):
F
NO2 (VI) with a compound of formula (VII):
N.---- N
I-1 (VII) in the presence of a metal halide, such as A1C13 under conditions sufficient to form the compounds of formula (V). X2 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. The variables, L1 and Q
are as defined in any of the embodiments described herein. In a preferred embodiment, X2 is Br or Cl. In one embodiment, Q is F, L1 is Br and X2 is Cl. The solvents used in the reaction include, but are not limited to, CH3NO2, acetonitrile, dichloromethane, dichloroethane, benzene, toluene and combinations thereof. In one embodiment, the solvent is dichloroethane.
F
NO2 (VI) with a compound of formula (VII):
N.---- N
I-1 (VII) in the presence of a metal halide, such as A1C13 under conditions sufficient to form the compounds of formula (V). X2 is selected from Br, Cl, I, tosy1-0-, mesy1-0-, trifluoromethanesulfony1-0-, CF3C(0)0- or CH3C(0)0-. The variables, L1 and Q
are as defined in any of the embodiments described herein. In a preferred embodiment, X2 is Br or Cl. In one embodiment, Q is F, L1 is Br and X2 is Cl. The solvents used in the reaction include, but are not limited to, CH3NO2, acetonitrile, dichloromethane, dichloroethane, benzene, toluene and combinations thereof. In one embodiment, the solvent is dichloroethane.
[0046] In another aspect, the present invention provides a method for preparing a compound of formula (III):
Q
I, Y 1 \ \ F H N1\
N N
H (III).
In one embodiment, the method comprises coupling, sulfonylation and deprotection steps.
For example, the method comprises:
(i) contacting a compound of formulas (I)or (Ia) with an agent of the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula :Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 *
Y
\ F NHP1 I
N N
\
p2 (IV);
(ii) reacting a compound of formula (IV) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX):
Q
0 =//0 Y
1 \ \ F HN1\
N N
\
p2 (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III).
Q
I, Y 1 \ \ F H N1\
N N
H (III).
In one embodiment, the method comprises coupling, sulfonylation and deprotection steps.
For example, the method comprises:
(i) contacting a compound of formulas (I)or (Ia) with an agent of the formula : Y-B(0R5)2 (i.e., formula IVb) or the formula :Y-Sn(Bu)3 (i.e., formula IVc) and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IV):
Q
0 *
Y
\ F NHP1 I
N N
\
p2 (IV);
(ii) reacting a compound of formula (IV) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (IX):
Q
0 =//0 Y
1 \ \ F HN1\
N N
\
p2 (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III).
[0047] Alternatively, the compounds of formula (III) can be prepared by carrying out sulfonylation reaction first, followed by Suzuki coupling and removing of the protecting group P2. For example, the method comprises:
(i) contacting a compound of formula (I) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (VIM:
Q
0 .0 1 \ F HN1\
N N
\
p2 (VIII);
(ii) reacting a compound of formula (VIII) with an agent of the formula (IVb):
Y-B(0R5)2 or formula (IVc): Y-Sn(Bu)3 and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
P1 and P2 are as defined in any of the embodiments as described herein;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S. In some instances, at each occurrence, at least two of the R8, R9 and R1 groups are not simultaneously hydrogen. In one embodiment, Q is F. In another embodiment, Q is H. In yet another embodiment, Y is 4-chlorophenyl; Z is propyl; Q is F; R5 is -OH; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
(i) contacting a compound of formula (I) with an agent of the formula: A1-S(0)2-Z (i.e., formula IVa) under conditions sufficient to form a compound of formula (VIM:
Q
0 .0 1 \ F HN1\
N N
\
p2 (VIII);
(ii) reacting a compound of formula (VIII) with an agent of the formula (IVb):
Y-B(0R5)2 or formula (IVc): Y-Sn(Bu)3 and a palladium or a nickel complex under conditions sufficient to form a compound of formula (IX); and (iii) removing the protecting group P2 under conditions sufficient to form the compound of formula (III), wherein:
Q is H or F;
P1 and P2 are as defined in any of the embodiments as described herein;
R5 is ¨OH, Ci_6alkyl or two ¨0R5 substituents together with the boron atom to which they are attached form an optionally substituted 5 or 6-membered ring;
A1 is a leaving group;
Y is optionally substituted aryl or optionally substituted heteroaryl; and Z is ¨N(R6)(R7) or ¨C(R8)(R9)(R10); wherein:
R6 and R7 are each independently selected from the group consisting of H, optionally substituted Ci_6alkyl, optionally substituted C3_8cycloalkyl, optionally substituted C3_8cycloalkylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl; or R6 and R7 taken together with the nitrogen atom to which they are attached form a four to eight-membered ring having from 0-2 additional heteroatoms as ring members selected from N, 0 or S, wherein the four to eight-membered ring is optionally substituted; and R8, R9 and R1 are each independently H, optionally substituted Ci_6alkyl, optionally substituted, Ci_6haloalkyl, optionally substituted Ci_6haloalkoxy, optionally substituted C3_8cycloalkyl, optionally substituted C3_ 8cycloalkylalkyl, optionally substituted aryl, optionally substituted arylalkyl, optionally substituted heterocycloalkyl, optionally substituted heterocycloalkylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl or -X2R11, wherein X2 is -NR12, 0 or S; R12 is H, Ci_6alkyl or aryl; and R11 is H, Ci_6alkyl, Ci_6haloalkyl, Ci_6haloalkoxy, C3_8cycloalkyl, C3_ 8cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, wherein R11 is optionally substituted with from 1 to 3 Re substituents selected from halogen, -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -0Rf, -SRf, -0C(0)R, -0C(S)R, -C(0)R, -C(S)R, -C(0)OR, -C(S)OR, -S(0)R, -S(0)2R, -C(0)NHRf, -C(S)NHRf, -C(0)NRfRf, -C(S)NRfRf, -S(0)2NHRf, -S(0)2NRfRf, -C(NH)NHRf, -C(NH)NRfRf, -NHC(0)Rf, -NHC(S)Rf, -NRfC(0)Rf, -NRfC(S)Rf, -NHS(0)2R, -NRfS(0)2Rf, -NHC(0)NHRf, -NHC(S)NHRf, -NRfC(0)NH2, -NRfC(S)NH2, -NRfC(0)NHRf, -NRfC(S)NHRf, -NHC(0)NRfRf, -NHC(S)NRfRf, -NRfC(0)NRfRf, -NRfC(S)NRfRf, -NHS(0)2NHRf, -NRfS(0)2NH2, -NRfS(0)2NHRf, -NHS(0)2NRfRf, -NRfS(0)2NRfRf , -NHRf, -NRfRf and Rf, wherein Rf is Ci-6alkyl, C3_6cycloalkyl, heterocycloalkyl, heteroaryl or aryl, wherein Rf is optionally substituted with from 1-3 Rg substituents selected from -CN, -CH=CH2, -OH, -NH2, -NO2, -C(0)0H, -C(S)OH, -C(0)NH2, -C(S)NH2, -S(0)2NH2, -NHC(0)NH2, -NHC(S)NH2, -NHS(0)2NH2, -C(NH)NH2, -OR", -SR", -0C(0)Rh, -0C(S)Rh, -C(0)Rh, -C(S)R", -C(0)OR", -C(S)OR", -S(0)Rh, -S(0)2R", -C(0)NHRh or Rh, wherein Rh is Ci_6alkyl; or any two of the R8, R9 and R1 groups taken together with the carbon atom to which they are attached form a 3 to 8-membered optionally substituted non-aromatic ring having from 0 to 2 heteroatoms selected from N, 0 or S. In some instances, at each occurrence, at least two of the R8, R9 and R1 groups are not simultaneously hydrogen. In one embodiment, Q is F. In another embodiment, Q is H. In yet another embodiment, Y is 4-chlorophenyl; Z is propyl; Q is F; R5 is -OH; P1 is H; and P2 is 2,6-dichlorophenylcarbonyl.
[0048] The agents Y-B(0R5)2 (i.e., formula IVb) or Y-Sn(Bu)3 (i.e., formula IVc) are either commercially available or can be readily prepared in accordance with the procedures described in the literature. In some embodiments, -B(0R5)2 is:
2-....< 2 ________ 0-\
-I3 ,µ -131\ y -B(01-)2 13`
, O'c , 0 r 0 In one embodiment, Y-B(0R5)2 is Y-B(OH)2. Y is as defined in any of the embodiments as described herein.
2-....< 2 ________ 0-\
-I3 ,µ -131\ y -B(01-)2 13`
, O'c , 0 r 0 In one embodiment, Y-B(0R5)2 is Y-B(OH)2. Y is as defined in any of the embodiments as described herein.
[0049] The agent A1-S(0)2-Z (i.e., formula IVa) is either commercially available or can be readily prepared in accordance with the procedures described in the literature. The leaving group A1 can be Cl, Br, I, tosy1-0-, mesy1-0, CF3S(0)20-, CF3C(0)0- or CH3C(0)0-. In one embodiment, A1 is Cl.
[0050] In some embodiments of compounds of formula (III), Y is selected from phenyl, 2-pyridyl, 3-pyridyl, 4-pyridy1,2-pyrazinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-imidazolyl, 4-imidazolyl, 1-pyrazolyl, 2-pyrazolyl, 3-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazoly1 or 5-isothiazolyl, each of which is optionally substituted with from 1-3 Re groups; or 1-3 Rf groups; or 1-3 Rg groups; or 1-3 Rh groups. In certain instances, Re is F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, ethyl, CH30, Et0-, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino, 1-hydroxy-1-methylethyl, methylcarbamoyl, 1-carboxycyclopropyl, 1-carbamoylcyclopropyl, 1-methoxycarbonylcyclopropyl, 1-cyanoisopropyl, 1-hydroxycyclopropyl, 1-hydoxyisopropyl, cyclobutoxy, cyclopentoxy, cyclohexyloxy, 4-morpholino, 4-hydroxypiperidiny1,1- piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, azetidinyl, pyrrolidinyl, cyclopropylcarbamoyl, 5-methy1-1,2,4-oxadiazol-3-yl, 5-methyl-1,3,4-oxadiazol-2y1, 5-dimethylamino-1,3,4-oxadiazol-2y1 or 5-methylamino-1,3,4-thiadiazol-2-yl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0051] In some embodiments of compounds of formula (III), Y is phenyl, 1-naphthyl or 2-naphthyl, each of which is optionally substituted with from 1-3 substituents selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-l-methylethyl or methylcarbamoyl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0052] In some embodiments of compounds of formula (III), Y is selected from 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2- thiophenyl, 3-thiophenyl, 2-amino-quinazolin-5-yl, 2-amino-quinazolin-6-yl, 2-amino-quinazolin-6-yl, 2-amino-quinazolin-7-yl, 2-amino-quinazolin-8-yl, 2-oxo-6-indolinyl, 2-oxo-4-indolinyl, 2-oxo-5-indolinyl, 2-oxo-7-indolinyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-y1 or 1H-indazol-7-yl, each of which is substituted with from 1 to 2 substituents independently selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, C2H50-, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, 1-carboxycyclopropyl, 1-carbamoylcyclopropyl, 1-methoxycarbonylcyclopropyl, 1-cyanoisopropyl, 1-hydroxycyclopropyl, 1-hydoxyisopropyl, cyclobutoxy, cyclopentoxy, cyclohexyloxy, 4-morpholino, 4-hydroxypiperidiny1,1- piperidinyl, piperazinyl, 4-methylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, azetidinyl, pyrrolidinyl, cyclopropylcarbamoyl, 5-methy1-1,2,4-oxadiazol-3-yl, 5-methyl-1,3,4-oxadiazol-2y1, 5-dimethylamino-1,3,4-oxadiazol-2y1, 5-methylamino-1,3,4-thiadiazol-2-yl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, isopropyl, 1-pyrrolidinyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-l-methylethyl. In certain instances, Y is 4-chlorophenyl. In other instances, Y is 4-pyrimidinyl or 5-pyrimidinyl, each of which optionally substituted with from 1, 2, or 3 substituents independently selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, 1-cyanocyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, isopropyl, 1-pyrrolidinyl, 1-cyclopropylethyl, 2-cyclopropylethyl, 1-cyclopropylethylamino, 2-cyclopropylethylamino or 1-hydroxy-1-methylethyl. The other variables Q and Z are as defined in any of the embodiments as described herein.
[0053] In some embodiments of compounds of formula (III), Z is 1-azetindinyl, pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl or 1-hexahydropyridazinyl, each of which is optionally substituted with from 1-3 Re groups.
In certain instances, Re is F, CH3, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. The other variables Q and Y are as defined in any of the embodiments as described herein.
In certain instances, Re is F, CH3, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0054] In some embodiments of compounds of formula (III), Z is selected from 1-azetindinyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl, 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl or 1-hexahydropyridazinyl, each of which is optionally substituted with from 1-2 R' substituents selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3- morpholinyl. In certain instances, R' is F, CH3, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. The other variables Q
and Y
are as defined in any of the embodiments as described herein.
and Y
are as defined in any of the embodiments as described herein.
[0055] In some embodiments of compounds of formula (III), Z is Ci_6alkyl, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cycloheptyl or cyclooctyl, each of which is optionally substituted with from 1-3 RJ groups selected from F, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxtetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3-morpholinyl. In one embodiment, Z is propyl. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0056] In some embodiments of compounds of formula (III), Z is selected from the group consisting of cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cycloheptyl, cyclooctyl, 1-azetindinyl, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, 4-thiomorpholinyl 3-oxazolidinyl, 3-thiazolidinyl, 2-isoxazolidinyl, 2-isothiazolidinyl, 1-pyrazolidinyl, 1-piperazinyl, 1-hexahydropyrimidinyl, 1-hexahydropyridazinyl, (CH3)(CF3CH2)N-, cycloproyplmethylamino, sec-butyl, pentan-2-y1 and pentan-3-yl, each of which is optionally substituted with from 1-2 R" groups selected from F, Cl, Br, I, -CN, -OH, -CF3, NH2, CF30-, CH3-, CH30, -NO2, cyclopropyl, cyclopropylmethyl, cyclopropylamino, cyclopropylmethylamino, 1-cyanocyclopropyl, methylamino, dimethylamino, methylthio, acetoxy, acetyl, methoxycarbonyl, acetamido, methylcarbamoyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl, 2-oxetanyl, 3-oxtetanyl, 2-oxetanylmethyl, 3-oxetanylmethyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrofuranylmethyl, 3-tetrahydrofuranylmethyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 4-morpholinyl, 2-morpholinyl or 3- morpholinyl. In one instance, Rk is -F, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH-, vinyl, propen-3-y1 or CH3(C0)(CH3)N-. In another instance, Rk is -F, methoxycarbonyl, ethoxycarbonyl, -CH3, CH3(CO)NH- or CH3(C0)(CH3)N-. In yet another instance, Rk is vinyl or propen-3-yl. The other variables Q and Y are as defined in any of the embodiments as described herein.
[0057] Various palladium or nickel complexes can be used for the preparation of compounds of formula (III). Preferably, palladium phosphine complexes are used in the reaction. The palladium complexes include, but are not limited to, Pd(PPh3)4, PdC12(PPh3)2, bis[1,2-bis(diphenylphosphino)ethane]palladium, bis(tri-t-butylphosphine)palladium, diacetobis(triphenylphosphine)palladium, tris(dibenzylideneacetone)dipalladium (Pd2(dba)2), Pd(OAc)2, dichloro[1,1'-bis(diphenylphosphino)ferrocene]palladium(II), and dichloro[1,1'-bis(di-i-propyl-phosphino)ferrocene]palladium (II). In one embodiment, the palladium complex is PdC12(PPh3)2. The palladium complexes can be present between 0.01 and 0.1 equivalents, e.g., about 0.01, 0.02, 0.025, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09 or 0.1 equivalents. Exemplary nickel complexes include, but are not limited to, NiC12(dppf), bis(tricyclohexylphosphine) nickel(II) chloride (NiC12(PCy3)2) and NiC12(PPh3)2.
[0058] The Suzuki coupling reaction can be carried out in various solvents, including, but not limiting to, toluene, dioxane, THF, 2-methyl-THF, water or a mixture thereof In one embodiment, the reaction is carried out in dioxane or 2-methyl-THF. The reaction can be performed at a temperature between 50-100 C, 60-90 C or 70-85 C. In one embodiment, the reaction is carried out using 0.025-0.05 eq of PdC12(PPh3)2, 2-3 eq of K2CO3 or NaHCO3, 1 eq of compound of formula (I), 1.5-2 eq of compound of formula (IVb), 10 volumes of dioxane and 5 volumes of water.
[0059] The sulfonylation reaction can be carried out in various solvents including, but not limiting to, pyridine, dichloromethane, THF, acetonitrile, toluene, dioxane, 2-methyl-THF or a mixture thereof Excess solvents can be used during the reaction, for example, the solvents can be from 1-5 equivalents, such as 1, 1.5, 2, 2.5, 3, or 4 equivalents. The temperature for the reaction can be maintained from about 50-110 C, e.g., 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105 or 110 C. In one embodiment, the reaction is carried out in a mixed solvents of pyridine and 10 volumes of dioxane at about 100 C.
[0060] The deprotection reaction can be conducted by reacting a compound of formula (IX) with NH3 dissolved in an organic solvent at a temperature from about 50-110 C, e.g., 50, 55, 60, 65, 70, 80, 85, 90, 95, 100, 105 or 110 C. The solvents used include, but are not limited to, methanol (Me0H), ethanol (Et0H), dimethylformamide (DMF), dimethylacetamide (DMA), THF, dimethylsulfoxide (DMSO), dioxane, isopropanol (IPA) or combinations thereof In one embodiment, the reaction can be conducted at 55 C in the presence of NH3 (5 eq), Me0H (5 eq, 10 volumes) and DMA (5 volumes). In another embodiment, the reaction can be conducted at 100 C in the presence of THF (5 volumes) and NH3/IPA (12 eq).
Examples
Examples
[0061] The following examples are offered to illustrate, but not to limit the claimed invention.
[0062] Certain molecules claimed in this patent can exist in different enantiomeric and diastereomeric forms and all such variants of these compounds are claimed.
[0063] Those skilled in the art will also recognize that during standard work up procedures in organic chemistry, acids and bases are frequently used. Salts of the parent compounds are sometimes produced, if they possess the necessary intrinsic acidity or basicity, during the experimental procedures described within this patent.
Example 1: Preparation of (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-y1)-(2,6-dffluoro-3-nitro-phenyl)methanone (3) Scheme 1 Br F
0 .CI 40 1 N.-.--N
H Br ,..
F AlC13 1 --,.... \ F NO2 CH2Cl2 2 NO2 N " 3 H
Example 1: Preparation of (5-bromo-1H-pyrrolo[2,3-b]pyridin-3-y1)-(2,6-dffluoro-3-nitro-phenyl)methanone (3) Scheme 1 Br F
0 .CI 40 1 N.-.--N
H Br ,..
F AlC13 1 --,.... \ F NO2 CH2Cl2 2 NO2 N " 3 H
[0064] To an 50-liter flask was added 1,2-dichloroethane (DCE, 20 L), followed by 5-bromoazaindole (1) (2 kg, 10.152 mol) to result an orange slurry. Aluminum Chloride (5.421 kg, 40.608 mol) was slowly added to the flask. The first 1.5 kg of the addition was exothermic resulting a dark solution. The rest of the A1C13 was added to give a reaction mixture. To the reaction mixture was added 2,6-difluoro-3-nitrobenzoyl chloride 2 (2.25 kg, 10.125 mol) via an addition funnel over a period of 1.5 h. During the addition, the reaction temperature was maintained at or below 45 C. After the addition, the reaction mixture was stirred at 50 C overnight, cooled to room temperature (-22 C) and transferred into two separate 20 L flasks. Water (25 L) and acetonitrile (12 L) were added to a 50-liter flask and cooled to 0 C. The reaction mixture was quenched by adding water/acetonitrile solution while keeping the temperature at or below 40 C. The mixture obtained was filtered, and the filtrate was washed with acetonitrile:water (1:1, 2x4 L), water (4 L) and acetonitrile (4 L), followed by drying in vacuum. Compound 3 (2.948 kg, 73.4% yield) was obtained.
MS
(ESI): M-411 = 382.9 and 383.9. 1H NMR (DMSO-d6, 6 ppm): 7.55 (1 H, m), 8.47 (2 H, m), 8.53 (1 H, d, J=2.2 Hz), 8.65 (1H, d, J = 2.2Hz), 13.25 (1 H, s).
Example 2: Preparation of (3-amino-2,6-difluoro-phenyl)-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (4) Scheme 2.
F
F
.
0 .
SnCl2 Br Br F NH2 1 `,, \ F NO2 2-methyl-THF I
N ,,, I ,,, N " 4 " 3 H
H
MS
(ESI): M-411 = 382.9 and 383.9. 1H NMR (DMSO-d6, 6 ppm): 7.55 (1 H, m), 8.47 (2 H, m), 8.53 (1 H, d, J=2.2 Hz), 8.65 (1H, d, J = 2.2Hz), 13.25 (1 H, s).
Example 2: Preparation of (3-amino-2,6-difluoro-phenyl)-(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)methanone (4) Scheme 2.
F
F
.
0 .
SnCl2 Br Br F NH2 1 `,, \ F NO2 2-methyl-THF I
N ,,, I ,,, N " 4 " 3 H
H
[0065] A 50-liter flask was added 2-methyl-tetrahydrofuran (2-methyl-THF) (36 L), compound 3 (2.85 kg, 7.455 mol) and tin(II) chloride (5.03 kg, 22.365 mol).
The mixture was heated to 60 C. Upon completion, the reaction was quenched with an aqueous potassium carbonate solution (20%). The resulting mixture was filtered with celite and the solid residue was washed with 2-methyl-THF and tetrahydrofuran (THF). The filtrate was washed with an aqueous NaC1 solution (15 L,10%) and the organic layer was separated. The organic layer was further washed with an aqueous NaC1 solution (15 L, 20%) and concentrated on a rotovap to yield compound 4 (2.536 kg, 96.65% yield). MS
(ESI): M+H ' =
353 and 354. iti NMR (DMS0- d6, 6 ppm): 5.22(2 H, s), 6.93 (2 H, m), 8.12(1 H, s), 8.47 (1 H, d J=2.3 Hz), 8.54 (1 H, d J-1.6 Hz), 13.2 (1 H, s).
Example 3: Preparation of (3-amino-2,6-difluoro-phenyl)-[5-bromo-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (5) Scheme 3.
F
F 0 .
0 ilt 2,6-dichlorobenzoyl chloride Br \ F NH2 Br , I
\ F NH2 õ, triethylamine, 2-methyl-THF N " Cl N N
Cl P---=
The mixture was heated to 60 C. Upon completion, the reaction was quenched with an aqueous potassium carbonate solution (20%). The resulting mixture was filtered with celite and the solid residue was washed with 2-methyl-THF and tetrahydrofuran (THF). The filtrate was washed with an aqueous NaC1 solution (15 L,10%) and the organic layer was separated. The organic layer was further washed with an aqueous NaC1 solution (15 L, 20%) and concentrated on a rotovap to yield compound 4 (2.536 kg, 96.65% yield). MS
(ESI): M+H ' =
353 and 354. iti NMR (DMS0- d6, 6 ppm): 5.22(2 H, s), 6.93 (2 H, m), 8.12(1 H, s), 8.47 (1 H, d J=2.3 Hz), 8.54 (1 H, d J-1.6 Hz), 13.2 (1 H, s).
Example 3: Preparation of (3-amino-2,6-difluoro-phenyl)-[5-bromo-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (5) Scheme 3.
F
F 0 .
0 ilt 2,6-dichlorobenzoyl chloride Br \ F NH2 Br , I
\ F NH2 õ, triethylamine, 2-methyl-THF N " Cl N N
Cl P---=
[0066] Compound 4 (2.5 kg, 7.114 mol) obtained from Example 2 was added into a 50-liter flask and cooled to 9.3 C. To compound 4 in the 50-liter flask was added triethylamine (0.864 kg, 8.537 mol), followed by 4-dimethylaminopyridine (DMAP) (0.087 kg, 0.7114 mol) and 2,6-dichlorobenzoyl chloride (1.34 kg, 6.40 mol) in 2-methyl-THF (25 L) over a period of 2 hrs. The reaction was quenched with methanol (0.30 L at room temperature and added an aqueous NaC1 solution (12.5 L, 15%) and celite (0.5 kg). The mixture was stirred and filtered through celite. The filtrate was concentrated and added 5 volumes of heptanes.
The resulting solution was stirred for about 1 hr and dried with sodium sulfate (1 kg) and filtered. Compound 5 was isolated by removing the solvents under vacuum (3.47 kg, 92.93%
yield). MS (ESI): M+FI1 = 524, 525.8, 527.8. 1H NMR (DMSO-d6, 6 ppm): 5.36 (2 H, s), 7.01 (2 H, m), 7.68 (3 H, s), 8.34 (1H, brs), 8.61 (1 H, brs), 8.72 (1 H, d J=2.3 Hz).
Example 4: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 4.
F F
0 . CI
to 0 PdC12(PPI13)2 / NaHCO3 CI 0 =
Br \ I F
NH2 ___________________________________________ . NH2 CI \ I
, 2-Me-THF / water / reflux FCI
IN
N B N N
0 104 HOõOH
The resulting solution was stirred for about 1 hr and dried with sodium sulfate (1 kg) and filtered. Compound 5 was isolated by removing the solvents under vacuum (3.47 kg, 92.93%
yield). MS (ESI): M+FI1 = 524, 525.8, 527.8. 1H NMR (DMSO-d6, 6 ppm): 5.36 (2 H, s), 7.01 (2 H, m), 7.68 (3 H, s), 8.34 (1H, brs), 8.61 (1 H, brs), 8.72 (1 H, d J=2.3 Hz).
Example 4: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 4.
F F
0 . CI
to 0 PdC12(PPI13)2 / NaHCO3 CI 0 =
Br \ I F
NH2 ___________________________________________ . NH2 CI \ I
, 2-Me-THF / water / reflux FCI
IN
N B N N
0 104 HOõOH
[0067] Under a nitrogen atmosphere, a 50-liter flask is charged with compound 5 (1.735 kg, 3.304 mol) prepared from Example 3 in 2-methyl-THF, boronic acid 6 (0.877 kg, 5.617 mol), PdC12(PPh3)2 (0.116 kg, 0.165 mol) and an aqueous sodium bicarbonate (0.833 kg, 9.912 mol) solution (8.7 L). The reaction mixture is degassed and heated to reflux for 7 hrs and stirred at room temperature overnight. Compound 6 (129.0 g) and PdC12(PPh3)2 (6.6 g) are added again and the reaction mixture is heated to reflux for another 5 hrs. Celite (1.735 kg) is added and the mixture is stirred for 30 minutes and then filtered through a pad of celite.
The residue is washed with 2-methyl-THF. The organic layer is separated, washed with a 10% NaC1 aqueous solution (4 L) for three times, further washed with a 20%
NaC1 aqueous solution, filtered, and dried over Na2504. The filtrate is concentrated by removing about 80-85% of solvent, added ethyl acetate (3.5 L) and stirred overnight. The mixture is filtered and washed with ethyl acetate (2x3.5 L) twice. Compound 7, is isolated after removing the solvents and drying at 45 C for 48 hrs (2.765 kg, 74% yield).
Example 5: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 5.
F
41), F
Or Pyridine CI
_,... 0 lik ,-.... \ F NH2 k I + \ F
Dioxane N'S CI CI' '0 I
ci N N reflux N N
0 ip, 8 CI CI
The residue is washed with 2-methyl-THF. The organic layer is separated, washed with a 10% NaC1 aqueous solution (4 L) for three times, further washed with a 20%
NaC1 aqueous solution, filtered, and dried over Na2504. The filtrate is concentrated by removing about 80-85% of solvent, added ethyl acetate (3.5 L) and stirred overnight. The mixture is filtered and washed with ethyl acetate (2x3.5 L) twice. Compound 7, is isolated after removing the solvents and drying at 45 C for 48 hrs (2.765 kg, 74% yield).
Example 5: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 5.
F
41), F
Or Pyridine CI
_,... 0 lik ,-.... \ F NH2 k I + \ F
Dioxane N'S CI CI' '0 I
ci N N reflux N N
0 ip, 8 CI CI
[0068] To a compound 7 (2.76 kg, 4.961 mol) in dioxane (25 L) is added pyridine (3.92 kg, 49.6 mol), followed by compound 8 (2.42 kg, 16.99 mol). The reaction mixture is heated to reflux and stirred overnight. The dioxane solvent is removed by distillation and the reaction is quenched by adding a mixture of ethyl acetate (16 L) and water (14 L). The reaction mixture is filtered and the filtrate is separated into an organic and an aqueous layer. The organic layer is washed with a 10% NaC1 aqueous solution (20 L) followed by a 20% NaC1 aqueous solution (20 L). The organic layer is separated, stirred in the presence of activated carbon (350 g) and filtered through celite. Compound 9 is isolated by removing the solvents under vacuum (1.81 kg, 52% yield).
Example 6: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10) Scheme 6.
F F
CI el 0 441t 0 0 0 4t 7N NH3 / Me0H N." S
I \ F
N N ___________________ .
H
Example 6: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10) Scheme 6.
F F
CI el 0 441t 0 0 0 4t 7N NH3 / Me0H N." S
I \ F
N N ___________________ .
H
[0069] To a high pressure vessel is added compound 9 (1.70 kg, 2.567 mol) in THF (5 L), followed by an ammonia/isopropyl alcohol solution (30.80 mol of ammonia in 12 L of isopropyl alcohol). The mixture is heated to 100 C overnight. When the reaction is completed, the solvents are removed in vacuum and the residue is dissolved in isopropanol.
Compound 10 is isolated and further purified by recrystallization using a mixture of THF (7 L) and isopropanol (14 L). Yield: 0.763 kg (60.7%).
Example 7: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 7.
0 NH2 is NH2 F
Br F I 0 I . F F
, 0 , \ , 0 N C
C B(OH)2 N CI v.-(Ph3P)2PdC12 N N CI
0 40 NaHCO3 2-MeTHF/Water CI
Compound 10 is isolated and further purified by recrystallization using a mixture of THF (7 L) and isopropanol (14 L). Yield: 0.763 kg (60.7%).
Example 7: Preparation of (3-amino-2,6-difluoro-phenyl)45-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridin-3-yl]methanone (7) Scheme 7.
0 NH2 is NH2 F
Br F I 0 I . F F
, 0 , \ , 0 N C
C B(OH)2 N CI v.-(Ph3P)2PdC12 N N CI
0 40 NaHCO3 2-MeTHF/Water CI
[0070] Compound 5 (900g; 1.7 mol) compound 6 (375.8g; 1.4 mol), sodium bicarbonate (302.6g; 2.1 mol) followed by 3-methyl-THF (9 L) and water (4.5 L) were added to the 20L
reactor and the mixture was purged with nitrogen at least for lh. Bis-triphenylphospino-palladium (II) chloride (60.8g; 0.086 mol) was added and the reaction mixture was heated to 70-75 C and stirred for 2h. The reaction mixture was cooled and filtered over celite pad.
The organic layer of the filtrate was separated, washed with water, and concentrated under vacuum. The precipitated solid was isolated by filtration and dried to provide compound 7 (953.9g) as a brown solid (Purity= 95.1%; Yield = ¨100%). 1H NMR (DMSO-d6): 6 (ppm) 8.75-8.76 (d, J = 2.2 Hz, 1H), 8.59 (m, 1H), 8.52 (s, 1H), 7.80-7.82 (d, J=8.6 Hz, 1H), 7.69-7.71 (m, 3H), 7.54-7.56 (d, J = 8.6 Hz, 2H), 6.99-7.07 (m, 2H), and 5.36 (s, 2H). MS (ESI) [M+H]1 = 556.1 and 558.1.
Example 8: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 8.
A
2 L., a 0 a 0 401 0, b N N CI ________ a- N N CI
Pyridine / DMAP
o Si 15-20 C o Si CI CI
reactor and the mixture was purged with nitrogen at least for lh. Bis-triphenylphospino-palladium (II) chloride (60.8g; 0.086 mol) was added and the reaction mixture was heated to 70-75 C and stirred for 2h. The reaction mixture was cooled and filtered over celite pad.
The organic layer of the filtrate was separated, washed with water, and concentrated under vacuum. The precipitated solid was isolated by filtration and dried to provide compound 7 (953.9g) as a brown solid (Purity= 95.1%; Yield = ¨100%). 1H NMR (DMSO-d6): 6 (ppm) 8.75-8.76 (d, J = 2.2 Hz, 1H), 8.59 (m, 1H), 8.52 (s, 1H), 7.80-7.82 (d, J=8.6 Hz, 1H), 7.69-7.71 (m, 3H), 7.54-7.56 (d, J = 8.6 Hz, 2H), 6.99-7.07 (m, 2H), and 5.36 (s, 2H). MS (ESI) [M+H]1 = 556.1 and 558.1.
Example 8: Preparation of N4345-(4-chloropheny1)-1-(2,6-dichlorobenzoyl)pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (9) Scheme 8.
A
2 L., a 0 a 0 401 0, b N N CI ________ a- N N CI
Pyridine / DMAP
o Si 15-20 C o Si CI CI
[0071] Compound 7 (800g; 1.44 mol) and dimethylamino pyridine (7.2g; 0.059 mol), under nitrogen, were added to a 5L three-necked-round bottom flask cooled in an ice water bath.
Anhydrous pyridine (1.8L) was charged and the mixture was stirred at 10-15 C
until a homogeneous solution was obtained. Propane-l-sulfonyl chloride (308g; 2.16 mol) was added drop-wise from an addition funnel while keeping the reaction temperature <20 C and the reaction mixture was stirred at 20-25 C for 3h. The reaction mixture was added to a mixture of 2-methyl-THF (7L) and water (10L) in a flask and the organic layer was separated, washed with 1N HC1 (2L) followed by brine (2L), and dried. The residue was azeotroped with toluene to remove the residual water to provide crude compound 9 (1116.4g) which was used in the next step without purification.
Example 9: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10).
Scheme 9.
H
0 N,Is ei o"b H
CI N s F F I
CI el lel o"b N N CI
NH3 /Me0H I I 0 THF
CI
Anhydrous pyridine (1.8L) was charged and the mixture was stirred at 10-15 C
until a homogeneous solution was obtained. Propane-l-sulfonyl chloride (308g; 2.16 mol) was added drop-wise from an addition funnel while keeping the reaction temperature <20 C and the reaction mixture was stirred at 20-25 C for 3h. The reaction mixture was added to a mixture of 2-methyl-THF (7L) and water (10L) in a flask and the organic layer was separated, washed with 1N HC1 (2L) followed by brine (2L), and dried. The residue was azeotroped with toluene to remove the residual water to provide crude compound 9 (1116.4g) which was used in the next step without purification.
Example 9: Preparation of N-[345-(4-chloropheny1)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl]propane-1-sulfonamide (10).
Scheme 9.
H
0 N,Is ei o"b H
CI N s F F I
CI el lel o"b N N CI
NH3 /Me0H I I 0 THF
CI
[0072] Crude compound 9 and THF (6L) were added to a 12L round-bottom flask and stirred until the clear solution was obtained. A solution of ammonia in methanol (1.24L; 7M) was added and stirred for 24h at 28-35 C. The reaction mixture was concentrated to near dryness after with methanol was added and concentrated at 45-50 C. The separated solid was filtered and dried at 45-50 C under vacuum to obtain crude compound 10 (601.7g; Purity = > 95%;
Yield = 85.4%). Recrystallization of the crude in acetone/methanol (2:1) provided compound in 74% yield with a purity of 98.5%. 1H NMR (DMSO-d6):6 (ppm) 9.78 (s, 1H), 8.72-8.73 (d, J=2.2 Hz, 1H), 8.65 (brs, 1H), 8.26 (s, 1H), 7.79-7.82 (d, J = 8.5 Hz, 2H), 7.57-7.61 (m, 3H), 7.28-7.32 (t, J = 8.3 Hz, 1H), 2.50-2.52 (m, 2H), 1.73-1.78 (m, 2H), and 0.96-0.98 (t, 3H). MS (ESI) [M+H'] ' = 490.1 and 492.1.
Yield = 85.4%). Recrystallization of the crude in acetone/methanol (2:1) provided compound in 74% yield with a purity of 98.5%. 1H NMR (DMSO-d6):6 (ppm) 9.78 (s, 1H), 8.72-8.73 (d, J=2.2 Hz, 1H), 8.65 (brs, 1H), 8.26 (s, 1H), 7.79-7.82 (d, J = 8.5 Hz, 2H), 7.57-7.61 (m, 3H), 7.28-7.32 (t, J = 8.3 Hz, 1H), 2.50-2.52 (m, 2H), 1.73-1.78 (m, 2H), and 0.96-0.98 (t, 3H). MS (ESI) [M+H'] ' = 490.1 and 492.1.
[0073] All patents, patent applications and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, to the same extent as if each reference had been incorporated by reference in its entirety individually.
[0074] One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims
[0075] While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention
[0076] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group.
[0077] Also, unless indicated to the contrary, where various numerical values are provided for embodiments, additional embodiments are described by taking any two different values as the endpoints of a range. Such ranges are also within the scope of the described invention.
Claims (20)
1. A compound of formula (I):
wherein:
Q is F or H;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
wherein:
Q is F or H;
P1 is hydrogen or a labile protecting group;
P2 is an amino protecting group or hydrogen; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
2. The compound of claim 1, wherein P1 is -H.
3. The compound of claim 1, wherein P1 is selectively cleaved in the presence of P2.
4. The compound of claim 3, wherein P1 is 9-fluorenylmethoxycarbonyl, t-butoxycarbonyl, trimethylsilyl or t-butyldiphenylsilyl.
5. The compound of any of claims 1-4, wherein P2 is an amino protecting group selected from R3-C(O)- or R4O-C(O)-, wherein R3 and R4 are each independently selected from C1-6alkyl, aryl, heteroaryl, aryl-C1-2alkyl, heteroaryl-C1-2alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-C1-2alkyl, ethynyl or vinyl, each of which is optionally substituted.
6. The compound of claim 5, wherein P2 is -H.
7. The compound of claim 5, wherein P2 is 2,6-dichlorophenylcarbonyl.
8. The compound of any of claims 5, wherein R3 or R4 is optionally substituted with 1-3 Ra groups independently selected from halogen, C1-6alkyl, fluoro substituted C1-6alkyl, fluoro substituted C1-6alkoxy, aryl, heteroaryl, C1-6alkoxy, -CN, -NO2, -OH, C1-6alkyl-OC(O)-, C1-6alkyl-C(O)O- or -SiMe3, wherein the aliphatic or aromatic portion of R a is further optionally substituted with from 1-3 R b groups independently selected from halogen, C1-6alkyl, C1-6alkoxy, -CN, -NO2 or -OH.
9. The compound of claim 8, wherein R a is F, Cl, Br, I, -CH3, Phenyl, t-butyl, MeO-, -NO2, -CN, -CF3, CF3O-, -OH or -CH=CH2.
10. The compound of any of claims 1-9, wherein R3 and R4 are each independently methyl, ethyl, phenyl, 2,2,2-trichloroethyl, (CH3)2CHC.ident.C-, 2-trimethylsilylethyl, 1-methyl-1-phenylethyl, cyclobutyl, cyclopropyl, allyl, vinyl, 1-adamantyl, benzyl or diphenylmethyl, each of which is optionally substituted with from 1-3 R a groups.
11. The compound of any of claims 1-10, wherein L1 is Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, R1-SO2O- or R2C(O)O, wherein R1 and R2 are each independently selected from aryl, aryl-C1-4alkyl or C1-6alkyl, each of which is optionally substituted with from 1-3 R c substituents selected from halogen, -CH=CH2, -CN, -OH, -NH2, -NO2, -C(O)OH, -C(O)NH2, -S(O)2NH2, -NHC(O)NH2, -NHC(S)NH2, -NHS(O)2NH2, -C(NH)NH2, -OR d, -SR d, -OC(O)R d, -C(O)R d, -C(O)OR d, -C(S)OR d, -S(O)R d, -S(O)2R d, -C(O)NHR d, -C(O)NR d R d, -S(O)2NHR d, -S(O)2NR d R d, -C(NH)NHR d, -C(NH)NR d R d, -NHC(O)R d, -NR d C(O)R d, -NHS(O)2R d, -NR d S(O)2R d, -NHC(O)NHR d, -NHR d or -NR d R d, wherein each R
d is independently selected from C1-6alkyl or aryl.
d is independently selected from C1-6alkyl or aryl.
12. The compound of claim 11, wherein L1 is Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-.
13. The compound of claim 1, wherein P1 is H; P2 is 2,6-dichlorophenylcarbonyl; and L1 is Br.
14. The compound of claim 1, wherein P1 is H; P2 is H; and L1 is Br.
15. A method for preparing a compound of formula (Ia), said method comprising:
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O-; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
P2 is an amino protecting group;
Q is H or F; and L1 is Br, Cl, I, R1-SO2O- or R2C(O)O-; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
16. A method for preparing a compound of formula (I) said method comprising:
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
reacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I);
wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
X3 is a leaving group;
P1 is a labile protecting group;
P2 is an amino protecting group;
Q is H or F;
L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
contacting a compound of formula (II):
with an agent of the formula: P2-X1 under conditions sufficient to form the compound of formula (Ia):
reacting a compound of formula (Ia) with an agent of formula: P1-X3 under conditions sufficient to form the compound of formula (I);
wherein:
X1 is selected from Br, Cl, I, tosyl-O-, mesyl-O-, trifluoromethanesulfonyl-O-, CF3C(O)O- or CH3C(O)O-;
X3 is a leaving group;
P1 is a labile protecting group;
P2 is an amino protecting group;
Q is H or F;
L1 is Br, Cl, I, R1-SO2O- or R2C(O)O; wherein R1 and R2 are each independently optionally substituted aryl or optionally substituted C1-6alkyl.
17. The method of claim 15, wherein said contacting is carried out in the presence of triethylamine and 4-dimethylaminopyridine.
18. The method of claim 15 or 16, wherein L1 is Br.
19. The method of claim 15 or 16, wherein P2 is 2,6-dichlorophenyl; and L1 is Br.
20. The method of claim 15 or 16, wherein Q is F.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261653994P | 2012-05-31 | 2012-05-31 | |
US61/653,994 | 2012-05-31 | ||
US13/793,917 | 2013-03-11 | ||
US13/793,917 US9150570B2 (en) | 2012-05-31 | 2013-03-11 | Synthesis of heterocyclic compounds |
PCT/US2013/043400 WO2013181415A1 (en) | 2012-05-31 | 2013-05-30 | Synthesis of pyrrolo [2, 3 - b] pyridines |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2874555A1 true CA2874555A1 (en) | 2013-12-05 |
CA2874555C CA2874555C (en) | 2019-04-02 |
Family
ID=48577959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2874555A Active CA2874555C (en) | 2012-05-31 | 2013-05-30 | Synthesis of pyrrolo [2, 3 - b] pyridines |
Country Status (25)
Country | Link |
---|---|
US (2) | US9150570B2 (en) |
EP (1) | EP2861591B1 (en) |
JP (1) | JP6258301B2 (en) |
KR (1) | KR102078429B1 (en) |
CN (2) | CN104507937A (en) |
AR (1) | AR091159A1 (en) |
AU (1) | AU2013267325B2 (en) |
BR (1) | BR112014029454B1 (en) |
CA (1) | CA2874555C (en) |
CL (1) | CL2014003228A1 (en) |
CR (1) | CR20140576A (en) |
EA (1) | EA027928B1 (en) |
EC (1) | ECSP14033037A (en) |
ES (1) | ES2687300T3 (en) |
HK (1) | HK1206010A1 (en) |
IL (1) | IL235819B (en) |
MX (1) | MX2014014465A (en) |
MY (1) | MY168935A (en) |
NZ (1) | NZ630453A (en) |
PE (1) | PE20142335A1 (en) |
PH (1) | PH12014502613B1 (en) |
SG (1) | SG11201407851RA (en) |
TW (1) | TWI603970B (en) |
UY (1) | UY34825A (en) |
WO (1) | WO2013181415A1 (en) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
NZ582772A (en) | 2007-07-17 | 2012-06-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US8158636B2 (en) | 2008-05-19 | 2012-04-17 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI404719B (en) | 2009-04-03 | 2013-08-11 | Hoffmann La Roche | Compositions and uses thereof |
KR101821768B1 (en) | 2009-11-05 | 2018-01-24 | 리젠 파마슈티컬스 소시에떼 아노님 | Novel benzopyran kinase modulators |
CN106220623A (en) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | Compounds and methods for and indication thereof for kinases regulation |
EP2501236B1 (en) | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
AU2010336524B2 (en) | 2009-12-23 | 2015-10-08 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2012109075A1 (en) | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
TWI601725B (en) * | 2012-08-27 | 2017-10-11 | 加拓科學公司 | Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use |
AU2013312477B2 (en) | 2012-09-06 | 2018-05-31 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
PT2935248T (en) | 2012-12-21 | 2018-04-05 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
WO2014145051A1 (en) | 2013-03-15 | 2014-09-18 | Jiazhong Zhang | Heterocyclic compounds and uses thereof |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
KR20160013028A (en) | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | Compounds for kinase modulation, and indications therefor |
US9771369B2 (en) | 2014-03-04 | 2017-09-26 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
ES2774177T3 (en) | 2014-09-15 | 2020-07-17 | Plexxikon Inc | Heterocyclic compounds and uses of these |
WO2016083956A1 (en) | 2014-11-29 | 2016-06-02 | Shilpa Medicare Limited | Substantially pure vemurafenib and its salts |
WO2016164641A1 (en) | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
HUE047657T2 (en) | 2015-05-06 | 2020-05-28 | Plexxikon Inc | Synthesis of 1h-pyrrolo[2,3-b]pyridin derivatives that modulate kinases |
JP6946194B2 (en) | 2015-05-06 | 2021-10-06 | プレキシコン インコーポレーテッドPlexxikon Inc. | Solid form of compounds that regulate kinases |
WO2016191295A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN108137585B (en) | 2015-09-21 | 2021-10-22 | 普莱希科公司 | Heterocyclic compounds and their use |
BR112018011475A2 (en) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compounds and methods for kinase modulation and indication for kinase |
WO2017161045A1 (en) | 2016-03-16 | 2017-09-21 | Plexxikon Inc. | Compounds and methods for kinase modulation and indications therefore |
TW201815766A (en) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | Compounds and methods for IDO and TDO modulation, and indications therefor |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
JP7300394B2 (en) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | Protein kinase inhibition to promote liver regeneration or reduce or prevent hepatocyte death |
CA3056777A1 (en) | 2017-03-20 | 2018-09-27 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
US10428067B2 (en) | 2017-06-07 | 2019-10-01 | Plexxikon Inc. | Compounds and methods for kinase modulation |
KR102051625B1 (en) * | 2017-06-30 | 2019-12-02 | 주식회사 엘지화학 | Novel hetero-cyclic compound and organic light emitting device comprising the same |
CA3070505C (en) | 2017-07-25 | 2023-09-26 | Plexxikon Inc. | Formulations of a compound modulating kinases |
WO2019075243A1 (en) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
AU2018354423A1 (en) | 2017-10-27 | 2020-05-14 | Plexxikon Inc. | Formulations of a compound modulating kinases |
JP2021518367A (en) | 2018-03-20 | 2021-08-02 | プレキシコン インコーポレーテッドPlexxikon Inc. | Compounds and methods for IDO and TDO regulation, and signs for them |
CA3136224A1 (en) | 2019-04-09 | 2020-10-15 | Plexxikon Inc. | Condensed azines for ep300 or cbp modulation and indications therefor |
WO2021216898A1 (en) | 2020-04-23 | 2021-10-28 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
CN116322690A (en) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | Combination pharmaceutical anticancer therapies |
US11578971B2 (en) | 2021-02-12 | 2023-02-14 | Holloway Ndt & Engineering Inc. | Ultrasonic testing using a phased array |
Family Cites Families (302)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB145299A (en) | 1919-08-14 | 1920-07-02 | Carl Theodor Thorssell | Improvements in or relating to apparatus for the production of nitrogen products |
US2234705A (en) | 1940-04-12 | 1941-03-11 | Eastman Kodak Co | Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids |
US2413258A (en) | 1942-07-07 | 1946-12-24 | United Gas Improvement Co | Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters |
CH513136A (en) | 1966-10-21 | 1971-09-30 | Minnesota Mining & Mfg | Perfluoroalkylsulphonamides antimicrobial antiparasitic pesticidal pla - nt growth regulatory and pharmacological agents |
IL46853A0 (en) | 1974-03-20 | 1975-05-22 | Bayer Ag | Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides |
GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
CA1148562A (en) * | 1979-02-22 | 1983-06-21 | Alfred J. Bird | Catalyst for the hydrogenation of halogen substituted aromatic nitro compounds |
US4301159A (en) | 1980-06-20 | 1981-11-17 | Shionogi & Co., Ltd. | N-(Diethylaminoethyl)-2-alkoxy-benzamide derivatives |
AU547405B2 (en) | 1981-07-08 | 1985-10-17 | Sanofi | Amidobenzamides |
US4664504A (en) | 1983-01-20 | 1987-05-12 | Tokyo Shibaura Denki Kabushiki Kaisha | Image forming apparatus |
US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US4626513A (en) | 1983-11-10 | 1986-12-02 | Massachusetts General Hospital | Method and apparatus for ligand detection |
AU567140B2 (en) | 1984-01-06 | 1987-11-12 | Shionogi & Co., Ltd. | Sulphonamido-benzamide derivatives |
ATE56096T1 (en) | 1984-03-15 | 1990-09-15 | Immunex Corp | TEST FOR INSTANT DETECTION OF LIGANDS, TEST KIT AND ITS PREPARATION. |
IT1196133B (en) | 1984-06-06 | 1988-11-10 | Ausonia Farma Srl | FURANIC DERIVATIVES WITH ANTI-ULCER ACTIVITY |
US4714693A (en) | 1986-04-03 | 1987-12-22 | Uop Inc. | Method of making a catalyst composition comprising uniform size metal components on carrier |
DE3642315A1 (en) | 1986-12-11 | 1988-06-23 | Boehringer Mannheim Gmbh | NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS |
US5688655A (en) | 1988-02-10 | 1997-11-18 | Ict Pharmaceuticals, Inc. | Method of screening for protein inhibitors and activators |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US5658775A (en) | 1988-05-17 | 1997-08-19 | Sloan-Kettering Institute For Cancer Research | Double copy retroviral vector |
JP2528706B2 (en) | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | Pharmaceutical composition of dihydropyridine compound |
JP3082204B2 (en) | 1988-09-01 | 2000-08-28 | ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ | Recombinant retrovirus with an amphotropic and ecotropic host range |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
FR2649979B1 (en) * | 1989-07-20 | 1992-01-17 | Rhone Poulenc Chimie | PROCESS FOR HYDROGENATION OF HALOGENO NITROAROMATIC DERIVATIVES IN THE PRESENCE OF A SULFUR DERIVATIVE |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
DE4022414A1 (en) | 1990-07-13 | 1992-01-16 | Bayer Ag | SUBSTITUTED PYRROLO-PYRIDINE |
US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
DK0580860T4 (en) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Process for preparing a solid dispersion |
CA2113990A1 (en) | 1991-07-26 | 1993-02-18 | Frederick L. Moolten | Cancer therapy utilizing malignant cells |
US5632957A (en) | 1993-11-01 | 1997-05-27 | Nanogen | Molecular biological diagnostic systems including electrodes |
GB9127531D0 (en) | 1991-12-31 | 1992-02-19 | Fujisawa Pharmaceutical Co | Heterocyclic compound |
FR2687402B1 (en) | 1992-02-14 | 1995-06-30 | Lipha | NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM. |
JPH05236997A (en) | 1992-02-28 | 1993-09-17 | Hitachi Ltd | Chip for catching polynucleotide |
JPH06135946A (en) | 1992-10-30 | 1994-05-17 | Otsuka Pharmaceut Co Ltd | Pyrazine derivative |
AU686115B2 (en) | 1992-11-02 | 1998-02-05 | Fujisawa Pharmaceutical Co., Ltd. | Imidazo (I,2-a) pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation |
GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
CN1118598A (en) | 1993-03-01 | 1996-03-13 | 默克·夏普-道姆公司 | Pyrrolo-pyridine derivatives |
EP0687267B1 (en) | 1993-03-01 | 1999-09-01 | MERCK SHARP & DOHME LTD. | Pyrrolo-pyridine derivatives as ligands of dopamine receptor |
ES2134929T3 (en) | 1993-03-01 | 1999-10-16 | Merck Sharp & Dohme | PIRROLO-PIRIDINA DERIVATIVES AS LINKS FOR DOPAMINE RECEPTORS. |
US5576319A (en) | 1993-03-01 | 1996-11-19 | Merck, Sharp & Dohme Ltd. | Pyrrolo-pyridine derivatives |
JP3394777B2 (en) | 1993-05-27 | 2003-04-07 | セレクタイド コーポレーション | Topologically separated, encoded solid-phase library |
US5840485A (en) | 1993-05-27 | 1998-11-24 | Selectide Corporation | Topologically segregated, encoded solid phase libraries |
IT1265057B1 (en) | 1993-08-05 | 1996-10-28 | Dompe Spa | TROPIL 7-AZAINDOLIL-3-CARBOXYAMIDE |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
GB9319297D0 (en) | 1993-09-17 | 1993-11-03 | Wellcome Found | Indole derivatives |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
US5965452A (en) | 1996-07-09 | 1999-10-12 | Nanogen, Inc. | Multiplexed active biologic array |
US5486525A (en) | 1993-12-16 | 1996-01-23 | Abbott Laboratories | Platelet activating factor antagonists: imidazopyridine indoles |
US5360882A (en) | 1994-02-04 | 1994-11-01 | Isp Investments Inc. | Eutectic compositions of divinyl imidazolidone and vinyl caprolactam |
EP1195372A1 (en) | 1994-04-18 | 2002-04-10 | Mitsubishi Pharma Corporation | N-heterocyclic substituted benzamide derivatives with antihypertensive activity |
GB9408577D0 (en) | 1994-04-29 | 1994-06-22 | Fujisawa Pharmaceutical Co | New compound |
US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
GB9412719D0 (en) | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
US5763198A (en) | 1994-07-22 | 1998-06-09 | Sugen, Inc. | Screening assays for compounds |
GB9416162D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
WO1996005200A1 (en) | 1994-08-10 | 1996-02-22 | Merck Sharp & Dohme Limited | TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO[2,3-b]PYRIDINE |
GB9416189D0 (en) | 1994-08-10 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9420521D0 (en) | 1994-10-12 | 1994-11-30 | Smithkline Beecham Plc | Novel compounds |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5837815A (en) | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
GB2298199A (en) | 1995-02-21 | 1996-08-28 | Merck Sharp & Dohme | Synthesis of azaindoles |
GB9503400D0 (en) | 1995-02-21 | 1995-04-12 | Merck Sharp & Dohme | Therpeutic agents |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US6117681A (en) | 1995-03-29 | 2000-09-12 | Bavarian Nordic Research Inst. A/S | Pseudotyped retroviral particles |
GB9507291D0 (en) | 1995-04-07 | 1995-05-31 | Merck Sharp & Dohme | Therapeutic agents |
GB2299581A (en) | 1995-04-07 | 1996-10-09 | Merck Sharp & Dohme | 3-(Tetrahydropyridin-1-yl-methyl)pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes |
GB9511220D0 (en) | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
AU6526896A (en) | 1995-07-22 | 1997-02-18 | Rhone-Poulenc Rorer Limited | Substituted aromatic compounds and their pharmaceutical use |
US5866411A (en) | 1995-09-08 | 1999-02-02 | Pedersen; Finn Skou | Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector |
US5747276A (en) | 1995-09-15 | 1998-05-05 | The Scripps Research Institute | Screening methods for the identification of novel antibiotics |
WO1997016533A1 (en) | 1995-10-31 | 1997-05-09 | The Regents Of The University Of California | Mammalian artificial chromosomes and methods of using same |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6025155A (en) | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US5804585A (en) | 1996-04-15 | 1998-09-08 | Texas Biotechnology Corporation | Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin |
US5908401A (en) | 1996-05-08 | 1999-06-01 | The Aps Organization, Llp | Method for iontophoretic delivery of antiviral agents |
US5725838A (en) | 1996-05-31 | 1998-03-10 | Resolution Pharmaceuticals, Inc. | Radiolabeled D4 receptor ligands |
AU3568897A (en) | 1996-06-07 | 1998-01-05 | Eos Biotechnology, Inc. | Immobilised linear oligonucleotide arrays |
CN1077892C (en) | 1996-06-25 | 2002-01-16 | 武田药品工业株式会社 | Oxazolone derivatives and their use as anti-helicobacter pylori agents |
KR100576148B1 (en) | 1996-08-12 | 2006-05-03 | 미쯔비시 웰 파마 가부시키가이샤 | Medicines Comprising Rho Kinase Inhibitor |
JPH10130269A (en) | 1996-09-04 | 1998-05-19 | Nippon Chemiphar Co Ltd | Carboline derivative |
JPH1087629A (en) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | New isoquinoline derivative, and its medicinal use |
AU734841B2 (en) | 1996-11-19 | 2001-06-21 | Amgen, Inc. | Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
JP2001514506A (en) | 1997-03-07 | 2001-09-11 | トロピックス・インコーポレーテッド | Protease inhibitor analysis |
US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
WO1998047899A1 (en) | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
US6096718A (en) | 1997-06-05 | 2000-08-01 | Gene Targeting Corp. | Tissue specific adenovirus vectors for breast cancer treatment |
SG72827A1 (en) | 1997-06-23 | 2000-05-23 | Hoffmann La Roche | Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives |
AU8096798A (en) | 1997-06-27 | 1999-01-19 | Resolution Pharmaceuticals Inc. | Dopamine d4 receptor ligands |
US6235769B1 (en) | 1997-07-03 | 2001-05-22 | Sugen, Inc. | Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase |
US6826296B2 (en) | 1997-07-25 | 2004-11-30 | Affymetrix, Inc. | Method and system for providing a probe array chip design database |
PT901786E (en) | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical dispersions with enhanced bioavailability |
US6161776A (en) | 1997-08-12 | 2000-12-19 | Nibco Inc. | Multi-layered, porous mat turf irrigation apparatus and method |
AU8908198A (en) | 1997-08-15 | 1999-03-08 | Hyseq, Inc. | Methods and compositions for detection or quantification of nucleic acid species |
ES2225407T3 (en) | 1997-09-11 | 2005-03-16 | Bioventures, Inc. | METHOD FOR PRODUCING ORDERLY HIGH DENSITY PROVISIONS. |
US6178384B1 (en) | 1997-09-29 | 2001-01-23 | The Trustees Of Columbia University In The City Of New York | Method and apparatus for selecting a molecule based on conformational free energy |
US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
CZ299156B6 (en) | 1997-12-22 | 2008-05-07 | Bayer Corporation | Substituted heterocyclic ureas, pharmaceutical compositions in which they are comprised and their use |
CA2300197A1 (en) | 1997-12-23 | 1999-07-01 | Warner-Lambert Company | Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis |
WO1999051595A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
EP1067931A1 (en) | 1998-04-02 | 2001-01-17 | Merck & Co., Inc. (a New Jersey corp.) | Antagonists of gonadotropin releasing hormone |
AU3117899A (en) | 1998-04-02 | 1999-10-25 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
CA2326143A1 (en) | 1998-04-02 | 1999-10-14 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
JP2002510685A (en) | 1998-04-02 | 2002-04-09 | メルク エンド カムパニー インコーポレーテッド | Gonadotropin-releasing hormone antagonist |
EP1071423A1 (en) | 1998-04-02 | 2001-01-31 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6288234B1 (en) | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
JP3720264B2 (en) | 1998-08-17 | 2005-11-24 | 千寿製薬株式会社 | Glaucoma prevention / treatment agent |
IL141724A0 (en) | 1998-08-28 | 2002-03-10 | Scios Inc | INHIBITORS OF P38-α KINASE |
AU763758B2 (en) | 1998-08-28 | 2003-07-31 | Astrazeneca Ab | Novel compounds |
US6594527B2 (en) | 1998-09-18 | 2003-07-15 | Nexmed Holdings, Inc. | Electrical stimulation apparatus and method |
ID28362A (en) | 1998-09-18 | 2001-05-17 | Basf Ag | 4-AMINOPIROLOPIRIMIDINA AS A CINNAMER INVOLVEMENT |
US6350786B1 (en) | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
US6277628B1 (en) | 1998-10-02 | 2001-08-21 | Incyte Genomics, Inc. | Linear microarrays |
IT1303759B1 (en) | 1998-11-17 | 2001-02-23 | Dompe Spa | IMPROVED PROCEDURE FOR THE PREPARATION OF 7-AZAINDOLYL-3-CARBOXYLIC ACID. |
US6277489B1 (en) | 1998-12-04 | 2001-08-21 | The Regents Of The University Of California | Support for high performance affinity chromatography and other uses |
US20010001449A1 (en) | 1998-12-30 | 2001-05-24 | Thomas R. Kiliany | Low-pressure hydrocracking process |
KR20020009570A (en) | 1999-03-05 | 2002-02-01 | 도리이 신이찌로 | HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING NICOTINIC ACETYLCHOLINE α4β2 RECEPTOR |
US6792306B2 (en) | 2000-03-10 | 2004-09-14 | Biophoretic Therapeutic Systems, Llc | Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor |
HUP0105114A3 (en) | 1999-03-17 | 2002-09-30 | Astrazeneca Ab | Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation |
AR028475A1 (en) | 1999-04-22 | 2003-05-14 | Wyeth Corp | DERIVATIVES OF AZAINDOL AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION. |
US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
US6221653B1 (en) | 1999-04-27 | 2001-04-24 | Agilent Technologies, Inc. | Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids |
FR2793793B1 (en) | 1999-05-19 | 2004-02-27 | Adir | NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US6492406B1 (en) | 1999-05-21 | 2002-12-10 | Astrazeneca Ab | Pharmaceutically active compounds |
TWI234557B (en) | 1999-05-26 | 2005-06-21 | Telik Inc | Novel naphthalene ureas as glucose uptake enhancers |
CA2375734A1 (en) | 1999-06-03 | 2000-12-14 | Knoll Gmbh | Benzothiazinone and benzoxazinone compounds |
WO2001009121A2 (en) | 1999-07-30 | 2001-02-08 | Basf Aktiengesellschaft | 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
US6653151B2 (en) | 1999-07-30 | 2003-11-25 | Large Scale Proteomics Corporation | Dry deposition of materials for microarrays using matrix displacement |
WO2001024236A1 (en) | 1999-09-27 | 2001-04-05 | Infineon Technologies North America Corp. | Semiconductor structures having a capacitor and manufacturing methods |
GB9924962D0 (en) | 1999-10-21 | 1999-12-22 | Mrc Collaborative Centre | Allosteric sites on muscarinic receptors |
US20010008765A1 (en) | 1999-12-06 | 2001-07-19 | Fuji Photo Film Co., Ltd. | DNA chip and reactive solid carrier |
AR029423A1 (en) | 1999-12-21 | 2003-06-25 | Sugen Inc | COMPOSITE DERIVED FROM PIRROLO- [PIRIMIDIN OR PIRIDIN] -6-ONA, METHOD OF PREPARATION OF THESE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, A METHOD FOR REGULATING, MODULATING OR INHIBITING THE ACTIVITY OF THE PROTEIN QUINASA AND ONE METHOD MAMMALS DISEASE |
EP1255536B1 (en) | 1999-12-22 | 2006-06-28 | Sugen, Inc. | Indolinone derivatives for modulation of c-kit tyrosine protein kinase |
FR2805259B1 (en) | 2000-02-17 | 2002-03-29 | Inst Nat Sante Rech Med | NOVEL N-MERCAPTOACYL AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US20020061892A1 (en) | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
JP2001278886A (en) | 2000-03-28 | 2001-10-10 | Dai Ichi Seiyaku Co Ltd | Benzoxazine derivative and medicament containing the same |
GB0007934D0 (en) | 2000-03-31 | 2000-05-17 | Darwin Discovery Ltd | Chemical compounds |
US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
CA2413510C (en) | 2000-06-26 | 2007-12-11 | Lilly Icos Llc | Condensed pyrazindione derivatives |
JP4068958B2 (en) | 2000-06-26 | 2008-03-26 | ファイザー・プロダクツ・インク | Pyrrolo (2,3-D) pyrimidine compounds as immunosuppressants |
WO2002018346A1 (en) | 2000-08-31 | 2002-03-07 | Pfizer Products Inc. | Pyrazole derivatives and their use as protein kinase inhibitors |
US6618625B2 (en) | 2000-11-29 | 2003-09-09 | Leon M. Silverstone | Method and apparatus for treatment of viral diseases |
DE60206889T2 (en) | 2001-02-27 | 2006-07-27 | Astrazeneca Ab | PHARMACEUTICAL FORMULATION CONTAINING BICALUTAMIDE |
EP1378247B1 (en) | 2001-04-11 | 2016-08-24 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
WO2002085896A1 (en) | 2001-04-24 | 2002-10-31 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan |
GB0114417D0 (en) | 2001-06-13 | 2001-08-08 | Boc Group Plc | Lubricating systems for regenerative vacuum pumps |
EP1267111A1 (en) | 2001-06-15 | 2002-12-18 | Dsm N.V. | Pressurized fluid conduit |
WO2002102783A1 (en) | 2001-06-19 | 2002-12-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US7291639B2 (en) | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
SE0102300D0 (en) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
SE0102439D0 (en) | 2001-07-05 | 2001-07-05 | Astrazeneca Ab | New compounds |
UA75425C2 (en) | 2001-07-09 | 2006-04-17 | Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds | |
GB0117583D0 (en) | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
US6858860B2 (en) | 2001-07-24 | 2005-02-22 | Seiko Epson Corporation | Apparatus and method for measuring natural period of liquid |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
JP2003073357A (en) | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | Rho KINASE INHIBITOR COMPRISING AMIDE COMPOUND |
AU2002334355A1 (en) | 2001-09-06 | 2003-03-18 | Prochon Biotech Ltd. | Protein tyrosine kinase inhibitors |
WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
EP1452525A4 (en) | 2001-10-30 | 2005-01-26 | Nippon Shinyaku Co Ltd | Amide derivatives and drugs |
US20030119839A1 (en) | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
KR100669578B1 (en) | 2002-01-22 | 2007-01-15 | 워너-램버트 캄파니 엘엘씨 | 2-PYRIDIN-2-YLAMINO-PYRIDO[2,3-d]PYRIMIDIN-7-ONES |
EP2292615A1 (en) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
US20030236277A1 (en) | 2002-02-14 | 2003-12-25 | Kadow John F. | Indole, azaindole and related heterocyclic pyrrolidine derivatives |
US6884889B2 (en) | 2002-03-25 | 2005-04-26 | Bristol-Myers Squibb Co. | Processes for the preparation of antiviral 7-azaindole derivatives |
KR20040111445A (en) | 2002-03-28 | 2004-12-31 | 에자이 가부시키가이샤 | 7-Azaindoles as Inhibitors of c-Jun N-terminal Kinase for The Treatment of Neurodegenerative Disorders |
ATE457312T1 (en) | 2002-03-28 | 2010-02-15 | Eisai R&D Man Co Ltd | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES |
EP1495016A2 (en) | 2002-04-09 | 2005-01-12 | Astex Technology Limited | Heterocyclic compounds and their use as modulators of p38 map kinase |
UA78999C2 (en) | 2002-06-04 | 2007-05-10 | Wyeth Corp | 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6 |
AU2003247959B2 (en) | 2002-07-09 | 2010-07-29 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
TW200403243A (en) | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
US6878887B2 (en) | 2002-08-07 | 2005-04-12 | Matsushita Electric Industrial Co., Ltd. | Anti-malfunction mechanism for variable output device |
EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
EP1388541A1 (en) | 2002-08-09 | 2004-02-11 | Centre National De La Recherche Scientifique (Cnrs) | Pyrrolopyrazines as kinase inhibitors |
SE0202463D0 (en) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
CN102516417B (en) | 2002-09-06 | 2014-12-10 | 天蓝制药公司 | Cyclodextrin-based polymers for therapeutics delivery |
US20040142864A1 (en) | 2002-09-16 | 2004-07-22 | Plexxikon, Inc. | Crystal structure of PIM-1 kinase |
US6766199B2 (en) | 2002-10-10 | 2004-07-20 | Proventure (Far East), Limited | Skin/hair treatment method and system |
US7183241B2 (en) | 2002-10-15 | 2007-02-27 | Exxonmobil Research And Engineering Company | Long life lubricating oil composition with very low phosphorus content |
GB0226370D0 (en) | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
SE0203654D0 (en) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
CA2509711A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Piperidine derivatives as ccr5 antagonists |
EP1569647B1 (en) | 2002-12-13 | 2008-08-20 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
UA80171C2 (en) | 2002-12-19 | 2007-08-27 | Pfizer Prod Inc | Pyrrolopyrimidine derivatives |
US7696225B2 (en) | 2003-01-06 | 2010-04-13 | Osi Pharmaceuticals, Inc. | (2-carboxamido)(3-Amino) thiophene compounds |
SE0300119D0 (en) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300120D0 (en) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
US20050085463A1 (en) | 2003-01-23 | 2005-04-21 | Weiner David M. | Use of N-desmethylclozapine to treat human neuropsychiatric disease |
US8486447B2 (en) | 2003-02-03 | 2013-07-16 | Novartis Ag | Pharmaceutical formulation |
MXPA05008441A (en) | 2003-02-14 | 2005-10-19 | Wyeth Corp | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands. |
SE0300456D0 (en) | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
JP2007524374A (en) | 2003-02-28 | 2007-08-30 | プレキシコン,インコーポレーテッド | PYK2 crystal structure and use |
WO2004078756A2 (en) | 2003-03-06 | 2004-09-16 | Eisai Co., Ltd. | Jnk inhibitors |
US7612086B2 (en) | 2003-05-16 | 2009-11-03 | Eisai R & D Management Co. Ltd. | JNK inhibitors |
EP1648889B1 (en) | 2003-07-11 | 2008-10-29 | Warner-Lambert Company LLC | Isethionate salt of a selective cdk4 inhibitor |
CL2004001884A1 (en) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS. |
AR045595A1 (en) | 2003-09-04 | 2005-11-02 | Vertex Pharma | USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US20060281803A1 (en) | 2003-09-23 | 2006-12-14 | Lindsley Craig W | Pyrazole modulators of metabotropic glutamate receptors |
KR100793095B1 (en) | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Novel Sulfone Amide Derivatives Capable Of Inhibiting BACE |
US7449582B2 (en) | 2003-10-08 | 2008-11-11 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
DE10357510A1 (en) | 2003-12-09 | 2005-07-07 | Bayer Healthcare Ag | Heteroaryl-substituted benzenes |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
GB0330042D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them |
GB0330043D0 (en) | 2003-12-24 | 2004-01-28 | Pharmacia Italia Spa | Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them |
AU2004312215B2 (en) | 2003-12-24 | 2009-03-05 | Dupont Nutrition Biosciences Aps | Proteins |
WO2005080393A1 (en) | 2004-02-14 | 2005-09-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
GB0403635D0 (en) | 2004-02-18 | 2004-03-24 | Devgen Nv | Pyridinocarboxamides with improved activity as kinase inhibitors |
GB0405055D0 (en) | 2004-03-05 | 2004-04-07 | Eisai London Res Lab Ltd | JNK inhibitors |
JP2007527918A (en) | 2004-03-08 | 2007-10-04 | アムジェン インコーポレイテッド | Therapeutic modulation of PPAR gamma activity |
KR20050091462A (en) | 2004-03-12 | 2005-09-15 | 한국과학기술연구원 | Furopyrimidine compound and ddr2 tyrosine kinase activity inhibitor comprising the same |
CN103554104A (en) | 2004-03-30 | 2014-02-05 | 沃泰克斯药物股份有限公司 | Azaindoles useful as inhibitors of jak and other protein kinases |
CA2561724A1 (en) | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
EP1773305A2 (en) | 2004-05-25 | 2007-04-18 | Yale University Corporation | Method for treating skeletal disorders resulting from fgfr malfunction |
JP4842929B2 (en) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | Pyrrolopyrimidine derivatives useful for cancer treatment |
WO2005115374A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Crth2 receptor ligands for therapeutic use |
EP1755597A2 (en) | 2004-06-17 | 2007-02-28 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
EP1761520B1 (en) * | 2004-06-23 | 2008-07-09 | Eli Lilly And Company | Kinase inhibitors |
EP2325184A1 (en) | 2004-06-30 | 2011-05-25 | Vertex Pharmceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
US7140816B2 (en) | 2004-07-20 | 2006-11-28 | H&S Tool, Inc. | Multi-functional tube milling head |
WO2006015124A2 (en) | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
US7709645B2 (en) | 2004-07-27 | 2010-05-04 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7361764B2 (en) | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
US7626021B2 (en) | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
KR20070053237A (en) | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | Pyrrolo-pyridine kinase modulators |
US20060024361A1 (en) | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
EP1789393A2 (en) | 2004-07-30 | 2007-05-30 | GPC Biotech AG | Pyridinylamines |
WO2006063167A1 (en) | 2004-12-08 | 2006-06-15 | Smithkline Beecham Corporation | 1h-pyrrolo[2,3-b]pyridines |
CA2605738C (en) | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
FR2884821B1 (en) | 2005-04-26 | 2007-07-06 | Aventis Pharma Sa | SUBSTITUTED PYRROLOPYRIDINES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE |
WO2007013896A2 (en) | 2005-05-17 | 2007-02-01 | Plexxikon, Inc. | Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors |
NZ564065A (en) | 2005-05-20 | 2011-03-31 | Vertex Pharma | Pyrrolopyridines useful as inhibitors of protein kinase |
CA2605764A1 (en) | 2005-05-23 | 2006-11-30 | Teva Pharmaceutical Industries Ltd. | Amorphous cinacalcet hydrochloride and preparation thereof |
US8067638B2 (en) | 2005-06-21 | 2011-11-29 | Mitsui Chemicals, Inc. | Amide derivative and insecticide containing the same |
HUE027370T2 (en) * | 2005-06-22 | 2016-10-28 | Plexxikon Inc | Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors |
DE102005034406A1 (en) | 2005-07-22 | 2007-02-01 | Ratiopharm Gmbh | New salts of rosiglitazone |
GB0516156D0 (en) | 2005-08-05 | 2005-09-14 | Eisai London Res Lab Ltd | JNK inhibitors |
US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
WO2007109604A2 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
US7963673B2 (en) | 2006-05-30 | 2011-06-21 | Finn Bruce L | Versatile illumination system |
DK2848610T3 (en) | 2006-11-15 | 2017-11-06 | Ym Biosciences Australia Pty | Inhibitors of kinase activity |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
GB0624084D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
US8093246B2 (en) | 2006-12-14 | 2012-01-10 | Lexicon Pharmaceuticals, Inc. | O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (en) * | 2006-12-21 | 2012-08-24 | Plexxikon Inc | PIRROLO [2,3-B] PYRIDINES COMPOUNDS AS KINASE MODULATORS |
JP2010526848A (en) | 2007-05-11 | 2010-08-05 | エフ.ホフマン−ラ ロシュ アーゲー | Pharmaceutical composition for poorly soluble drugs |
CL2008001540A1 (en) | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compounds derived from pyrrolopyridines and pyrazolopyridines; pharmaceutical composition; and use in the treatment of cancer. |
NZ582772A (en) | 2007-07-17 | 2012-06-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
CA2691752C (en) | 2007-07-23 | 2016-01-26 | Evangelos Karavas | Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof |
JP2009077712A (en) | 2007-09-11 | 2009-04-16 | F Hoffmann La Roche Ag | DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-Raf KINASE INHIBITOR |
US20110003859A1 (en) | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
WO2009111277A1 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imdizo [4. 5-b] pyridine derivatives used as raf inhibitors |
CN102149712A (en) | 2008-02-29 | 2011-08-10 | 阵列生物制药公司 | Pyrazole [3, 4-b] pyridine Raf inhibitors |
WO2009111278A2 (en) | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
WO2009115084A2 (en) | 2008-03-20 | 2009-09-24 | Schebo Biotech Ag | Novel pyrrolopyrimidine derivatives and the use thereof |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
PE20091846A1 (en) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS |
US8110576B2 (en) * | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
JP5767965B2 (en) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | 5H-pyrrolo [2,3-B] pyrazine derivatives that regulate kinases and indications thereof |
RU2493157C2 (en) | 2008-08-20 | 2013-09-20 | Пфайзер Инк. | PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES |
AR074199A1 (en) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | COMPOSITE OF 6- (4-PYRIMIDINYL) -1H-INDAZOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OR DECREASE OF CANCER GRAVITY. |
EP2406259A1 (en) * | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
TW201036972A (en) | 2009-03-11 | 2010-10-16 | Plexxikon Inc | Compounds and uses thereof |
TWI404719B (en) | 2009-04-03 | 2013-08-11 | Hoffmann La Roche | Compositions and uses thereof |
TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
JP2013503189A (en) * | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | RAF inhibitory compounds and methods of use thereof |
CN106220623A (en) | 2009-11-06 | 2016-12-14 | 普莱希科公司 | Compounds and methods for and indication thereof for kinases regulation |
WO2011060216A1 (en) * | 2009-11-12 | 2011-05-19 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
EP2501236B1 (en) * | 2009-11-18 | 2017-03-29 | Plexxikon Inc. | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer |
AU2010336524B2 (en) * | 2009-12-23 | 2015-10-08 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI510487B (en) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
FR2964757B1 (en) | 2010-09-09 | 2013-04-05 | Giroptic | OPTICAL DEVICE FOR CAPTURING IMAGES ACCORDING TO A 360 ° FIELD |
EP2616467A1 (en) | 2010-09-13 | 2013-07-24 | Concert Pharmaceuticals Inc. | Substituted azaindoles |
WO2012109075A1 (en) * | 2011-02-07 | 2012-08-16 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
WO2012138809A1 (en) | 2011-04-05 | 2012-10-11 | Dawei Zhang | Heterocyclic compounds as kinase inhibitors |
WO2012158957A2 (en) | 2011-05-17 | 2012-11-22 | Plexxikon Inc. | Kinase modulation and indications therefor |
US20130172375A1 (en) | 2011-12-13 | 2013-07-04 | Hoffmann-La Roche Inc. | Pharmaceutical composition |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
KR20160013028A (en) * | 2013-05-30 | 2016-02-03 | 플렉시콘, 인코퍼레이티드 | Compounds for kinase modulation, and indications therefor |
ES2774177T3 (en) | 2014-09-15 | 2020-07-17 | Plexxikon Inc | Heterocyclic compounds and uses of these |
-
2013
- 2013-03-11 US US13/793,917 patent/US9150570B2/en active Active
- 2013-05-23 TW TW102118278A patent/TWI603970B/en active
- 2013-05-24 AR ARP130101826 patent/AR091159A1/en unknown
- 2013-05-24 UY UY0001034825A patent/UY34825A/en not_active Application Discontinuation
- 2013-05-30 BR BR112014029454-2A patent/BR112014029454B1/en active IP Right Grant
- 2013-05-30 KR KR1020147036080A patent/KR102078429B1/en active IP Right Grant
- 2013-05-30 CN CN201380027442.9A patent/CN104507937A/en active Pending
- 2013-05-30 PE PE2014002209A patent/PE20142335A1/en not_active Application Discontinuation
- 2013-05-30 AU AU2013267325A patent/AU2013267325B2/en active Active
- 2013-05-30 NZ NZ630453A patent/NZ630453A/en not_active IP Right Cessation
- 2013-05-30 WO PCT/US2013/043400 patent/WO2013181415A1/en active Application Filing
- 2013-05-30 EA EA201492165A patent/EA027928B1/en not_active IP Right Cessation
- 2013-05-30 MY MYPI2014703464A patent/MY168935A/en unknown
- 2013-05-30 ES ES13727790.1T patent/ES2687300T3/en active Active
- 2013-05-30 JP JP2015515193A patent/JP6258301B2/en active Active
- 2013-05-30 CA CA2874555A patent/CA2874555C/en active Active
- 2013-05-30 MX MX2014014465A patent/MX2014014465A/en unknown
- 2013-05-30 SG SG11201407851RA patent/SG11201407851RA/en unknown
- 2013-05-30 CN CN201811515969.7A patent/CN109608450A/en active Pending
- 2013-05-30 EP EP13727790.1A patent/EP2861591B1/en active Active
-
2014
- 2014-11-20 IL IL23581914A patent/IL235819B/en active IP Right Grant
- 2014-11-24 PH PH12014502613A patent/PH12014502613B1/en unknown
- 2014-11-27 CL CL2014003228A patent/CL2014003228A1/en unknown
- 2014-12-15 CR CR20140576A patent/CR20140576A/en unknown
- 2014-12-23 EC ECIEPI201433037A patent/ECSP14033037A/en unknown
-
2015
- 2015-07-06 HK HK15106422.8A patent/HK1206010A1/en unknown
- 2015-08-28 US US14/839,668 patent/US9695169B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2874555C (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
CA2986920C (en) | Synthesis of heterocyclic compounds | |
WO2020118683A1 (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
AU2023270260A1 (en) | Novel processes and intermediates for the preparation of soluble guanylate cyclase stimulators | |
EP4249077A1 (en) | Novel acridinium salt and method for producing same | |
Won et al. | Chan–Lam coupling reaction of sulfamoyl azides with arylboronic acids for synthesis of unsymmetrical N-arylsulfamides | |
CA3134902A1 (en) | Benzethers and anilines of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
Xu et al. | An improved synthesis of 2-oxa-7-azaspiro [3, 5] nonane and analogs as novel reagents in medicinal chemistry | |
CN115996727A (en) | Process for preparing Rho related protein kinase inhibitors and intermediates in the process | |
UA113984C2 (en) | INTERMEDIATE COMPOUNDS IN PYROLINE SYNTHESIS [2,3-b] | |
CN106458947A (en) | Crystalline derivatives of (s)-1-((2r,3r,4s,5s)-5-allyl-3-methoxy-4-(tosylmethyl)tetrahydrofuran-2-yl)-3-aminopropan-2-ol | |
WO2018153820A1 (en) | Process for the preparation of chiral pyrollidine-2-yl- methanol derivatives |